Please also visit GetIPT.com

Site outline:
Choosing IPT
Find a Doctor
IPT Training
About IPT
Other Diseases
Doctors Listing
Patient Stories
Patients Home
Articles & pubs
Site Index
About Us
Tell a Friend

This level:  
Syphilis 1938
Pyloric Stenosis
Donatian Therapy 1976
Uruguay 2003





Drs. Donato Perez Garcia



Donatian Therapy:  History
Donatian Therapy: Theory
Donatian Therapy: Practice

Therapeutic rationale
Schedule for a typical treatment
Enemas and cathartics
The use of insulin in Donatian therapy
Administration of medications and termination of hypoglycemic reaction
Adverse reactions, troubleshooting, etc.
Influences of diseases on Donatian therapy
Contraindications to Donatian therapy

Dr. Donato Perez Garcia's Practice of Donatian therapy
  [includes drugs and doses, and treatment notes]

Treatment plans for specific diseases (30 diseases)

appendicitis, acute
bladder, carcinoma of
bladder/kidneys, infection of
breast, carcinoma of
breasts, benign tumors/cysts of
bronchitis, chronic
bronchogenic carcinoma
cervix, carcinoma of
cervicitis/vaginitis, chronic
cholelithiasis, cholecystitis
colitis, ulcerative/mucus/mild chronic
colon, carcinoma of
dysmenorrhea *
epileptic conditions
hiatus hernia
hyperactive children
infections, acute, bacterial/viral
poliomyelitis, acute
poliomyelitis, chronic
prostate, cancer of
prostatic hypertrophy, benign
trauma to spinal cord with paralysis
ulcers, peptic, gastric, or duodenal
ulcers, gastric, malignant

Notes with respect to the treatment of malignant neoplastic disease
Oncodiagnosis: method and interpretation

Lists of pharmacological agents  
[includes brand name, manufacturer, generic name, ingredients, route of administration and usual dosage, and other treatment notes]

Pharmacological agents applied in primary therapy  [19 drugs]
Pharmacological agents applied in secondary therapy [68 drugs and mixtures]

Interim therapy





This presentation is about a form of medical therapy called Donatian Therapy.  It was named in honour of its innovator, the late Dr. Donato Perez Garcia, Sr., whose son, Dr. Donato Perez Garcia, Jr. is, at this writing, its sole practitioner.

            I met Dr. Perez in September, 1975, through a patient referral, and discovered that we shared a number of interests in medicine.  I arranged to visit him in Mexico in November, 1975, where I had the opportunity to observe his clinic.  On my return, I decided to compose this presentation on the history, theory, and practice of Donatian Therapy.

            I can make no valid comment on the efficacy of this scheme of medical therapeutics; such judgment can obviously be made only after comprehensive documentation of the results of clinical trials and follow-up over a period of time.  To date, this has not been undertaken adequately, neither by Dr. Perez nor any of his critics.

The sole objective of this presentation is, therefore, to create an awareness of this therapy and stimulate interest in testing it to the end of discovering, once and for all, whether its formulation is valid or not.  It is my opinion that such investigation, if its results should prove positive, would initiate a great advance in medical science, and if negative, would save many patients from false hopes and needless expense.


Donato Perez Garcia was born in Mexico City on October 22, 1896, the son of a stable hand and a domestic servant. Through his own determination and effort, he obtained an education and was graduated from the University of Mexico's medical school in 1924. By 1930, he had achieved the status of chief surgeon and instructor of surgery at the Central Military Hospital in Mexico City.

From his early youth Dr. Perez had suffered from a chronic gastrointestinal disorder that medicine of the time was unable to cure. In 1926, he chanced to read of a then newly discovered hormone, insulin, noting that it was indicated for the control of diabetes mellitus and was also useful in therapy for undernourishment. Since he was desperate for personal relief and for a chance to present his patients with a better example of health than his semi-emaciated condition, he decided to try insulin on himself.

He began daily intramuscular injections of insulin, following each injection with a full meal. From almost the first injection, his digestive function and general appearance improved greatly. Later, in order to control the timing of the onset of the symptoms of hypoglycemia more accurately, he began to inject the insulin intravenously. After several months of such self-experimental treatment, he found that he was able to discontinue the insulin and remain in a good state of health.

This experience led Dr. Perez to consider a new avenue of medical therapy. He reasoned that if insulin could aid in the assimilation of ingested food, it might have a like effect on applied medicines.

To test this hypothesis, he ran experiments on two groups of dogs: both groups received identical doses of mercury and arsenic salts, one without any antecedent preparation, and the other during the period of hypoglycemia following an intravenous injection of insulin. After sacrificing the animals and examining their brains and spinal cords, he found no traces of the salts in the brains of the first group; but in the second, the concentration of these salts in the brain tissue was nearly the same as their concentration in the blood. From this experiment, Dr. Perez concluded that insulin had permitted the blood-brain barrier to be breached.

Encouraged by these results, and in spite of the skepticism of his colleagues, Dr. Perez managed to arrange, in 1932, to divide his practice of medicine between surgery at the Central Military Hospital and the medical treatment of neurosyphilis in his private office. For the latter, he used conventional antisyphilitic therapy (mercury and arsenic) but preceded it with intravenous injections of insulin to induce hypoglycemia. This treatment produced cures in the majority of his patients.

Since these results were so gratifying, Dr. Perez continued his work, moving his clinic and working quarters into downtown Mexico City. During parts of 1937 and all of 1938, he went to the United States where he demonstrated his therapy at the Saint Elizabeth Hospital, Washington, D.C. and the Austin State Hospital, Austin, Texas. His work here produced the same striking results as it had in Mexico, and, after the 1938 visit, he was invited by Dr. Titus Harris of the University of Texas, in Galveston, to stay in the United States to study the treatment and publish his results.

This offer was appealing as it presented an excellent opportunity to work under proper research conditions and to make his therapy widely known, perhaps rather quickly. Nevertheless, Dr. Perez chose to return home. His experiences with too many American doctors had led him to feel that they were becoming over interested in medical specialization and that this tendency might keep them from being much interested in his treatment because it was so simple and applicable to so many fields. But the primary reason for his decision appears to have been patriotic: he wanted his discovery to come out of Mexico, not the United States.

So Dr. Perez worked on in Mexico, attempting to develop further applications of insulin therapy. In 1940, he started treating viral infections and other infectious diseases with it -using antibiotics, vitamins, and minerals in conjunction with the insulin -- and obtained good results. In 1946, he used it to cure a case of acute appendicitis without surgical intervention (a success that encouraged him to complete the transition from surgery to his own medical therapy and leave surgical practice altogether). Later in the same year, he first applied the therapy to a case of cancer - a cancer of the tongue, which had been diagnosed by biopsy at a hospital -- and obtained a cure. (I am told that, at the time of this writing, the patient still survives).

Dr. Perez's growing medical successes were not met with a complementary regard or even interest from his colleagues. Quite to the contrary, there was outright criticism of his actions to which he reacted angrily. The outcome of this disagreement was that Dr. Perez became ignored by those peers who did not scorn him outright; further, his publications were thenceforth not welcomed in the medical journals. (I can only speculate that Dr. Perez must have handled the controversy poorly, choosing to show them some spectacular successes to drive them out of their skepticism, rather than taking the cooler approach of producing long-term documentation of his results. This was evidently the wrong tack to have taken at that time, but such is the stuff of history).

Dr. Perez, however, was not without his admirers and supporters. Foremost among them was his only son, Donato, Jr.   Born November 18, 1930, he had grown up in living quarters over the Mexico City clinic and was well aware of the controversy surrounding his father's unconventional therapy. In 1949, he decided to help his father in seeking out the secret of the therapy and entered the study of medicine at the University of Mexico.

There seems to be little doubt that the student's path was made more difficult by his father's reputation. On hearing whose son he was, at least one professor told him he would fail him in his course and carried out the threat. But after five years of study, filled with frequent supplemental examinations and pleas to alternate professors, Donato, Jr. graduated as a doctor of medicine in 1955. Soon after, he joined his father in the clinic.

There the son recognized that his father was a single-minded man whom adversity had drawn into stubbornness, so he made no attempt to make even small changes in the therapy at this time. But he did begin some research projects on the patients treated so as to document a scientific basis that could be used in clarifying and proving the therapy for others.

Perhaps the most important of these was begun in 1957. For nine years, he gave each clinic patient blood tests before the administration of insulin, during the hypoglycemic phase, and after normoglycemia had peen reestablished with intravenous hypertonic glucose. In each sample, he determined the pH, p02, pC02, surface tension, glucose, cholesterol, creatinine, sodium, potassium, chloride, calcium, and magnesium. The documented results demonstrated that, in fact, insulin did bring about profound alterations in the physico-chemical constants of the blood, a conclusion that was consistent with the theory that the therapy was based on. The material was published privately, but it could not be distributed locally, although many copies were mailed out to university libraries all over the world.

Unfortunately, this report received little attention from the medical profession, and before it could be substantially supplemented, Dr. Perez, Jr.'s inclination towards research was halted by a spectacular incident.

One night, in 1966, a man came to the clinic with a gun. He was a local fourth-year medical student who had come to hate the Drs. Perez because of what he had been told about them by his clinical professors. His purpose was to kill them both. There were some dramatic moments that night, complete with the son interposing himself between his father and the assailant as they struggled for the gun. Although it went off, luckily no one was hurt, and the doctors managed to subdue the student. Lengthy explanations followed, ending with the student apologizing in tears and returning home lamenting that one didn't know who to believe anymore.

Although the incident had ended without physical harm to anyone, it had a lasting emotional effect on Dr. Perez, Jr.  Already embittered towards the medical establishment, he now decided to stop his efforts to convince them about the therapy and to discontinue his research work. He knew that the therapy worked, and he determined to just practice it with his father on their patients and let the rest of the medical world go its own way.

Then, in 1968, Dr. Perez, Jr. happened on what seemed to be an important diagnostic test for cancer. A patient came to see him who had had a left radical mastectomy for cancer of the breast. As a complication of this procedure, she had developed lymphedema of her left arm and was in constant pain. Dr. Perez could not see how he would be able to help her with any known therapy, even his father's cellular therapy, but he felt so strongly for her that he sought to develop some unconventional aid.

He approached the problem by thinking that he might be able to draw some fluid out of her arm through the skin by some sort of electrolysis procedure and thus relieve her pain. Trying to develop some practical application of this unconventional hypothesis, he took serum from five patients, measured exactly three cubic centimeters from each into a semi-permeable (pergamine) membrane sack, put each into a separate beaker of distilled water with copper wire electrodes in it, and turned on the voltage. The next day, when he was measuring the volume of fluid remaining in each sack, he saw that one of the samples had turned a deep purple. Checking the clinical histories on these patients, he discovered that this purple serum had come from the one patient out of the five who had cancer. With the exciting notion that he might just have stumbled across something very significant, he next ran serum samples from five known cancer patients through this set-up; they all came out purple.

Since that time, the Drs. Perez have used this test on all their patients and have found a high correlation between the observed color-change and the presence of malignant neoplastic disease diagnosed by other methods. Furthermore, they have discovered that, after sufficient applications of their therapy to a cancer patient, the test result would become negative coincident with a clinical cure.   Dr. Perez, Jr. gave the name "Oncodiagnosticador" to the simple machine that he designed to do these tests. Although the Drs. Perez used this machine in their clinic with what appears to them to be highly satisfactory results, their attempts to introduce it to the rest of the medical community met with no more success than their attempts to publicize their work with insulin therapy. So, father and son simply continued to work alone in their clinic.

Late in 1971, Dr. Donato Perez Garcia, Sr. died at his home of a cerebral thrombosis.

After his father's death, Dr. Perez, Jr. continued his practice of medicine, applying the insulin therapy. He did, however, make a few important modifications in it that he had not been able to effect while his father was alive. He started to give the insulin intramuscularly (instead of intravenously) and to use much lower doses. He also reduced the dosage of the various drugs given orally, intramuscularly, and intravenously, during the induced hypoglycemic phase of the treatment. He did this because he felt the effects would be less stressful on the patient without sacrificing anything in the way of therapeutic results. With all this, he continued to have excellent clinical results, yet he continued to work in isolation.

Once in a while he would leave this isolation -- more accurately, this isolation would leave him. The editor of a popular national magazine (Impacto) had once been treated successfully by Dr. Perez, Sr.  Every so often, out of gratitude, he would write an exposé on the amazing cancer cure of the Drs. Perez. Having this provocative subject publicized in this sort of journal did little, of course, to improve the relationship between the local medical community and Dr. Perez. But by this time, there was so little love lost between the two that Dr. Perez enjoyed the popular publicity, his primary concern being to publicize the therapy any way he could. However, the whole thing only served to show up the other doctors in an embarrassing way -- to the complete detriment of what he was trying to do. Possibly his mode of presentation was unacceptable "professionally" but, under his galling circumstances, understandable.  An impassioned frustration drove him to act in spite.  More of the stuff of history.  

In 1975, Dr. Perez finally received some more orthodox publicity, and perhaps the beginning of a chance for a new hearing. Fortune, rather than his own striving, initiated it. A Finnish biochemistry student was told that he had terminal cancer. But although the doctors were defeated by his case, the young man himself continued to search for help. Looking through a university library, he happened across a description of the Drs. Perez's therapy.  It was one of the numerous complimentary copies of their 1966 research publication that had been sent to all parts of the world.   Seizing on this possible solution, the young man went to Mexico and apparently was cured of his disease by applications of the Donatian Therapy. He returned to Finland in the summer of 1975 and reported his experience to Dr. Thomas Taalberg, of the University of Helsinki medical school.  Dr. Taalberg had knowledge of the student's previous condition and became actively interested in the whole affair.

He communicated his interest to Dr. Perez, who soon undertook to visit Finland and discuss his therapy with Dr. Taalberg. This was in August of 1975.

Following this meeting, Dr. Perez also conferred with representatives of the Bayer Pharmaceutical Company, in Germany, and the Hoffman-La Roche Company, in Switzerland.  He was well received in all these encounters.  At last, it seemed the ice was thinning a little. On his way back home to Mexico, Dr. Perez stopped off in Montreal, mostly because he had always admired Canada and Canadian medicine. "Insulin was discovered in Canada," he said.  "If only Banting and Best knew what they had done when they discovered the insulin!"

It was in Montreal that I met Dr. Perez, became interested in his therapy, and finally made arrangements to go to Mexico to see his work for myself. Afterwards, I decided to undertake the writing of this presentation.

At this point, I must again state that this paper is only intended to create an awareness of this subject within the medical profession. The proof, one way or the other, of what is described in the following sections can only be determined by a thorough clinical application of the principles of the therapy by a disinterested group.

I must say that, personally, I found my experience with Donatian Therapy a very exciting one. I must also add that I find it disappointing that neither Dr. Perez nor any other member of the Mexican medical profession has ever done the kind of research on the therapy that would have clarified the situation properly.

Nevertheless, I think I can understand why things have transpired as they have to date. Dr. Perez, Sr. started using a highly unconventional therapy in a way that the Mexican medical establishment was not able to appreciate at that time. He probably expected to be esteemed; when instead he was fiercely criticized, this self-made man reacted with bitterness. Rather than trying to convince his opponents, he stubbornly withdrew into the world of his clinic where only work, not proof, was demanded of him. This reclusiveness, whatever its origin, only led to less communication and more misunderstanding. The antagonism escalated. Dr. Perez, Jr., despite having spent his formative years in the middle of the controversy and having suffered for his father's views during his studies, did see the need for better research at the outset of his career. But the determined hostility of his peers, and his own reaction to this, soon drove him into isolation as well.

The breaking of this isolation by a sort of popular publicity that is repugnant to most professionals seemed to prove to many Mexican doctors that they had been right in branding him as a quack, while it fed Dr. Perez's feeling that he was doing the right thing in publicizing the therapy any way he could. The result was a stand-off; both sides "knew" they were right and neither was willing to communicate with the other as to proof.

The fact that the Drs. Perez came to use their therapy on cancer escalated the entire situation. Cancer is a highly emotional disease -- for both doctors and laymen -- and in a situation where the battle lines had already been drawn, its introduction as a factor served to harden them fast.

But no battle lines can last forever, and one would hope that, after thirty-odd years of bitterness, the medical profession would be able to forget emotions and personalities in the interests of science and humanity. The therapy exists, patients claim to have been helped by it, but no one has proved or disproved it. Therefore, my strongest motivation now is to study it, properly and professionally, but I do not have the facilities to do this on my own.

Dr. Thomas Taalberg of the University of Helsinki medical school and other elements of the European medical community are now pursuing an investigation of some aspects of this Donatian Therapy. It is my hope that a similar interest will develop within the Canadian medical establishment as a result of this presentation, and that this will lead in turn to a proper, professionally directed investigation of the Donatian Therapy in this country.


Donatian Therapy applies the actions of the hormone insulin on the human body, postulating that these actions produce an enhancement or potentiation of the effects of other medications that may be administered concurrently.

Physiologically, insulin's mode of action is still not fully understood. We do know that it facilitates the entrance of glucose into the cells and lowers the blood glucose by certain mechanisms: 1) increased cell-membrane permeability; and 2) encouragement of the use of glucose in the formation of glycogen in skeletal muscle and liver. Insulin also promotes the formation of fat in the adipose tissues and enhances protein synthesis. It is also known that insulin alters the concentrations of other physico-chemical constituents of the serum, such as potassium and phosphate. Donatian Therapy accepts these mechanisms and further deduces other important consequences of insulin's action:

I) A non-specific increase of cell-membrane permeability.

2) Favorable exosmosis and endosmosis conditions produced between the extracellular fluid (ECF) and the intracellular fluid (ICF) as consequences of the insulin-induced hypoglycemia followed by the hyperglycemia produced by the administration of a fifty-percent glucose solution.

3) Extensive physico-chemical alterations in the serum.

4) Other endocrine effects stimulated by the hypoglycemia.

Increased cell-membrane permeability. Common medical theory postulates that insulin triggers a phenomenon at the level of the cell membrane which permits glucose and other sugars to enter certain cells. Not all tissues respond identically here. Skeletal muscle and adipose tissue are insulin sensitive in this way, while brain and liver are considered non-insulin-sensitive with respect to this membrane phenomenon.

Animal experimentation*, however, has indicated that this insulin effect on cell membranes might be more widely applicable than is generally thought; specifically that it may also apply to brain tissue. This leaves open the question of its effect on other tissues, as well as the possibility that its action permits substances other than glucose to cross the cell-membrane barrier.

*[See History, page 1 paragraph 5, for the description of experiments using insulin to effect a change in the distribution of certain inorganic salts within the tissues of two groups of dogs. Documentation of this work was presented in Revista Medica Militar (private publication, Mexico City, 1938) in Spanish.

Donatian Therapy postulates: i) that insulin does indeed affect the permeability of the cell membranes of many tissues; and ii) that this increased permeability is non-specific, over and above its effects on glucose and other sugars, in that it allows many solutes in the ICF and ECF to traverse cellular membranes with greater facility. So, continues the theory, these phenomena enhance the mobilization of intracellular waste products into the ECF, and potentiate the effects of administered medications in the ICF.

Endosmosis/exosmosis conditions. Because of the increased permeability of cell membranes and the effects on the ECF and ICF concentrations of glucose that result from insulin's action and the subsequent administration of a hypertonic glucose solution, Donatian Therapy postulates:

1) The initial influx of glucose into the cells creates a favourable situation of exosmosis whereby intracellular solutes may more readily diffuse from the ICF to the ECF.

2) The administration of the hypertonic glucose solution produces a new situation of endosmosis whereby substances in the ECF are more prone to diffuse into the ICF.

3) Intracellular waste products and administered medications leave and enter the cells with greater facility on account of these osmotic phenomena created by manipulating the serum glucose concentration.

Physico-chemical alterations. Insulin causes profound changes in the therapeutic terrain as it stresses the basic metabolic processes of the cells of the body. The serum concentrations of glucose, the free fatty acids, the amino acids, and several electrolytes are all affected by insulin. These extensive physico-chemical alterations, together with the other endocrine factors, produce what is considered a positive change in this therapeutic terrain.

Other endocrine effects. The lowered glucose level in the blood produced by insulin's action sets in motion a number of physiological mechanisms. There is a direct stimulation of the adrenal medulla, resulting in an increased secretion of epinephrine. There is also an increased ACTH secretion by the pituitary, which stimulates a greater production of the glucocorticoid hormones by the adrenal cortex. The eventual result of these effects is to increase the glucose level of the blood through glycogenolysis and gluconeogenesis, and to inhibit any endogenous insulin secretion.

Epinephrine and the glucocorticoid hormones have far-reaching effects, over and above those relating to carbohydrate metabolism. With respect to the total organism, epinephrine is known as the "fight or flight" hormone, and the glucocorticoids are called the "stress" hormones. Could one not surmise that these hormonal actions apply also at the cellular level in a manner similar to their actions at the level of the total organism? In the acute reactive conditions of insulin-induced hypoglycemia, perhaps the cells of the body are "primed" to be more susceptible to the effects of specific therapeutic agents because of these induced hormone effects.


Donatian Therapy is an hypothesis relating these postulates (and their extensions) to each other and to the administration of various medications. The hypothesis is:

I) The increased permeability of the cell membrane permits substances to enter and leave the cells of the body more readily.

2) Acting synergistically with the increased membrane-permeability, the induced favourable exosmosis conditions allow metabolic waste products to leave the ICF to be excreted; subsequently, the endosmosis conditions favour the entrance of substances, such as medications, into the ICF where they act therapeutically, (i.e., cyclophosphamide.)

3) The increased permeability of the cell membranes and the situation of endosmosis allow immediate and therapeutically effective intracellular concentrations of medication to be obtained with a lower total dose of medication. This allows many dose-related side-effects of pharmacological agents to be avoided.

The foregoing endocrine effects, together with the multiple physico-chemical alterations, act to protect normal cells from any toxic action of medications administered to treat abnormal cells. 

The foregoing hypothesis was derived from a simple consideration of the physiological and pharmacological principles that seem to be involved when Donatian Therapy is applied.  However, biochemical documentation, based on applications of the therapy, is required to elucidate the theory of the therapy, as well as its efficacy.


The practice of Donatian Therapy is wholly consistent with the practice and principles of straightforward medical therapy. The only differences involve the use of insulin to induce the hypoglycemic state, and the subsequent therapeutic manipulations within this induced state. There are no differences in diagnostic or investigative procedures. One must always take a complete history and perform a thorough physical examination before considering therapy.


In discussing the therapeutic rationale of Donatian Therapy, it is useful to divide the treatment into primary, secondary, and tertiary levels.

Primary treatment.  The primary therapeutic endeavor in Donatian Therapy is detoxification* of the organism. This is accomplished through the use of combinations of drugs, acting in synergy with phenomena induced by the action of insulin within the organism, to promote the processes of transport, conjugation, and excretion of metabolic waste products.

[* The term "detoxification" is the best rendering I could think of for the word "disintoxication" that Dr. Perez used throughout our discussion. I feel that there are two factors contributing to the lack of precision in the terminology here: i) the wide scope of the primary therapeutic endeavor itself, and ii) the language difficulty.]

The elements of this primary treatment are:

I) Administration of insulin to create conditions favouring the mobilization of metabolic waste products in the general circulation.

2) Drugs that increase blood flow and enhance the eliminative functions of the renal, hepatobiliary, and gastrointestinal systems. These include vasodilators, vitamins and minerals, choleretics and cholagogues, diuretics, and smooth muscle stimulants.

3) Enemas and cathartics are used to initiate the detoxification process, cleansing the biliary and lower intestinal tracts through a combination of physical and pharmacological purging.

The therapy is carried out on an out-patient basis with the patient spending, on the average, six hours in bed at the clinic on the day of his treatment and then returning home. The treatments are usually repeated every eight days, the number of treatments depending on the diagnosis, the goals of therapy (curative, palliative, or rehabilitative), and the clinical response of the patient. The treatment interval is generally set at eight days because the experience has shown that the effects of the treatments start to subside after the ninth or tenth day. As the patient's condition improves under therapy, this interval can be lengthened in gradual one-week increments. Once the patient has passed a three-week interval without any signs or symptoms of relapse, he is considered cured. Certain acute conditions can be cured in a single treatment. This is the case with most viral and bacterial infections.

Secondary treatment.  In secondary treatment, specific pharmacological agents are applied to treat particular processes of cellular pathology. The endosmosis conditions produced at the time of the intravenous hypertonic glucose injection favour the diffusion of these drugs into the ICF [intracellular fluid].

This enhances the therapeutic effect of these medications while allowing lower total doses to be used in achieving the effective intracellular concentrations required. The choice of drugs to be used in this secondary treatment is determined by the diagnosis and the standard indicated therapy for same.

With accurate diagnosis and proper treatment, patients will experience the benefits of the treatment on the day following the treatment. Failure to obtain a significant clinical response in this manner is always an indication for reevaluation of the specifics of the therapeutic regimen.

Tertiary treatment.  Any set of circumstances in an individual's way of life that have led to the development of a particular disease will cause that disease to return after the supposed cure has been effected unless these circumstances are removed. This is a basic consideration.

In Donatian Therapy, one effects immediate improvement in the patient's condition through a combination of physico-chemical alterations acting synergistically with applied medicines.  Next, it is important to reinforce and maintain these changes so that the benefits of therapy can endure.

This is the aim of tertiary therapy. Its goals are accomplished through a program of preventive medicine. This program emphasizes good nutrition with nutritional supplements (vitamins, minerals, etc.) where indicated. As well, the patient is counseled with respect to the other elements important in health maintenance: pure water, fresh air, sunshine, exercise, adequate rest, and proper mental attitude.



9:00 A.M.: The patient arrives, fasting, with his first morning urine sample. Blood required for any indicated assays is drawn at this time.

9:15 A.M.: The patient, in bed in the left lateral position, is given an enema and an intramuscular injection containing a cathartic mixture.

11: 00 A.M.: Having been given sufficient time to evacuate his bowels, the patient is given his intramuscular dose of insulin with 1/2 cc vitamin B-complex in the same syringe. The patient is educated with respect to the symptoms of hypoglycemia and Instructed at what stage to call for his medications. The onset of symptoms of hypoglycemia is approximately one half hour after the injection, with the maximum desired stage of hypoglycemia, the "therapeutic moment," appearing 25 to 30 minutes after this.

12:00 P.M.: The patient is given his medications, first orally, then intramuscularly, and finally the intravenous medications are given in hypertonic glucose.  Following this, more 50% hypertonic glucose is injected intravenously until all the signs and symptoms of hypoglycemia have abated.

12:00 to 3:00 P.M.: The patient rests in bed, taking fruit juices sweetened with sugar or honey, sweetened gelatin desserts, and herb teas, as desired to overcome thirst or hunger, or to allay any further mild symptoms of low blood glucose. Most patients will sleep during this period.

3:00 P.M.: The patient is allowed to go home, accompanied by a family member or friend, and advised that for the rest of the day, he should:  i) keep a source of sweetness close at hand and ingest some as appetite or need should demand; ii) continue resting at his home; iii) remain fasting except for liquids, juices, etc. If hunger should become unbearable, the patient is permitted one slice of whole wheat bread or toast with honey and a glass of 2% or skim milk. Full alimentation may begin on the day after the treatment.


The intestinal tract, including the biliary tree, is one of the body's principal excretory systems. In the initial phase of primary treatment, this system is cleared with an enema and a combination of pharmacological agents having a cathartic action on the smooth muscle components of this system.

Because of the importance of the lower intestinal tract in the elimination of wastes, tertiary treatment is strongly implicated here also. For this, patients are advised to normalize their colonic function by avoiding purified carbohydrates (particularly white bread) and by taking a daily fibre supplement of unprocessed bran.

On the night before a treatment, the patient should take an oral cathartic preparation, such as magnesium salts, senna herb, or castor oil. On the morning of the treatment, the patient is given an enema. This enema consists of a 1000 cc volume of water containing 10 gm each of Na2SO4 and Na2CO3. These salts are added to act as irritants of the colonic mucosa, stimulating a more complete evacuation.

After the enema, the patient is given a single intramuscular injection combining the following: i) Pitocin 1/3 cc of 10 units/cc,  ii) Mestinon 1/3 cc of 1 mg/cc,  iii) Arlidin 1/3 cc of 5 mg/cc, and   iv) vitamin B-complex solution 1/3 cc. (The rationale for applying these specific agents here is given in the Lists of Pharmacological Agents, Primary Therapy.)

The combination of the enema with the salts and the intramuscular cathartic mixture is given in all cases as described, with the following qualifications and exceptions:

-After several treatments, the patient may complain of irritation in the colon from the enema. In these cases, the salts are omitted. If the patient continues to complain, then the IM cathartic is omitted as well, or the dosages can all be scaled down to 1/4 cc each. These may be reincluded later according to the clinical situation.

-In patients with severe hypertension, the IM cathartic mixture is omitted.

-In patients with mild or moderate hypertension, the IM cathartic is employed along with the enema, but with the doses all scaled down to 1/4cc.

-In patients with arteriosclerotic heart disease (angina pectoris, rhythm disturbances, history of cardiac decompensation), the IM cathartic is omitted and the patient is given a simple water enema without the salts.

-In children, one uses only 250 cc of water without the salts, and no IM cathartic. This volume is varied according to the size of the child. After 10 years of age, the IM cathartic is introduced, but with the 1/4 cc doses. With patients who have reached the age of 16 to 18, one is able to use the full amounts of both the enema and the IM cathartic.

-In schizophrenia, detoxification is most important. Here, instead of the 1/3 cc doses of the constituent medicines, one uses 2/3 cc of each along with the enema.

-In menstruating females, one omits the Pitocin from the IM cathartic.



Types and doses of insulin.  Except for cases of diabetes mellitus, one always employs crystalline, fast-acting insulin ( 40 units/cc). This is injected intramuscularly, together with 1/2 cc of vitamin B-complex solution.

Insulin dosage for inducing hypoglycemia in Donatian Therapy is, in the uncomplicated case, determined on the basis of the body weight.

A simple formula used is:   Units of insulin = ((Weight in Kg) / 72) - 5.

The experience is that for individuals who are vegetarians, the calculated dosage can be reduced by another 5 units. As a general rule, one should always employ the lowest dosage that one feels might be effective. Experience is important here.

In pediatric cases, the above rule does not apply. Instead : -For children less that 1 year of age, use 1/2 unit.

-For children 1 to 10 years of age, start off with 1--2 units and, according to the clinical response, increase it at each successive treatment by 1--2 units.

-For children 10 to 15 years of age, start off with 5 units, and, according to the clinical response, increase it by 2 units at each successive treatment.

As regards the dosages of insulin, these are just very safe guidelines. Clinical experience is the best guide for effective action in this area of the therapy.

Evaluation of response.   In a typical situation, 30 minutes after receiving his dose of insulin, the patient will notice the onset of the symptoms of hypoglycemia. The first to appear are thirst, hunger, and a very mild clouding of intellectual abilities. There is also an experience of vague anxiety. The maximum desired level of hypoglycemia is then reached 25 to 30 minutes later. At this stage, the patient has started to sweat all over his body, he has tachycardia, a fine tremor of his hands, and slightly more marked clouding of the intellect. This time is called the "therapeutic moment." Not all patients will experience all of these symptoms every time. It is important that all patients be thoroughly educated as to what they might expect from this part of the treatment.

The patient's reaction to his insulin dosage should be charted as "poor”, "good”, or "excessive”.

-A "poor" reaction is one where the patient feels nothing at all, or just very little of the described symptoms, by 2 hours after the injection.

-A "good" reaction has been described above.

-An "excessive" reaction is one where the patient has all of the symptoms described, but their onset is much faster and they are generally more accentuated. The clouding of mental ability is the key here. Patients should never lose their orientation in a normal treatment.



The time of the maximum desired hypoglycemia is called the "therapeutic moment”.

There is no exact or "best" time when this occurs, by the clock. Clinical judgment and experience guided by the commentary given on this subject above will make this concept clearer .

At the "therapeutic moment," the patient is first given his oral medications, taken with sips of water. The intramuscular medications, each one in a separate syringe, are given in the buttock through a single needle. The method of doing this is: using ordinary sterile procedures and a 1-1/2 inch #20 needle, the first drug is injected; the needle is then withdrawn 1/2 inch and reintroduced at a different angle, aspirating to check that it is not in a vein; the next syringe is attached, and the drug injected. This procedure is repeated for each of the intramuscular drugs. After all the IM drugs have been given, the needle is withdrawn and the area is massaged firmly. (When Imferon is one of the drugs used, the area is not massaged.)

Next, the intravenous medications are given, mixed with 50% hypertonic glucose in 10 cc syringes (i.e., approximately 1--3 cc of medication mixed with sufficient glucose solution to make up 10 cc).

Finally, 50% hypertonic glucose is given rapidly intravenously until all the symptoms of hypoglycemia are abolished. The average amount required is 100 cc, but there are large variations, both ways. The determining factor is always the clinical situation (tremor, sweating).



As a consequence of the induced hypoglycemia, there are a number of adverse reactions that may arise at different times on the day of the treatment.  These are:

Headache, nausea, diarrhea, fatigue, etc.   These may arise during the waiting period after the termination of the symptoms of hypoglycemia or, more commonly, later on in the day, after the patient has returned to his home. They are never severe. The patient should be forewarned about their possible occurrence, and advised to take aspirin for headache, anti-emetic suppositories for the nausea and vomiting, rest for the fatigue, and be assured that the diarrhea is an integral part of the therapeutic process, which it is in many cases. Sometimes the fatigue can linger on for two days after the therapy. Again, the patient should be assured that this is within normal limits.

Acute headache.   This occurrence is infrequent, but important. During the administration of the hypertonic glucose solution to end the hypoglycemia, the patient will start to complain of an occipital headache. The increased extra-cellular fluid volume of the injection plus fluid drawn into the vascular compartment by the osmotic effects of the hypertonic glucose solution has elevated the blood pressure. In these cases, the intravenous injection is discontinued, and the patient is given a quantity of sugar orally to put an end to the hypoglycemic state.

Leg cramps.   This usually occurs during the period of observation between the giving of the medicines and the time that the patient is permitted to leave. This is a manifestation of a need for more sugar and so the patient should be encouraged to take this. The patient should also be given 100 mg of nicotinic acid orally.

Bloating.   Some patients over-zealously imbibe fluids after therapy and end up with a simple stomach ache. They should be encouraged to continue taking sugar but in solid rather than liquid form. In rare cases, it may be necessary to give the patient 500 cc of 10% dextrose in water intravenously.

Muscular pains.   Sometimes, on the day after a treatment, the patient will experience a myositis-like pain in his extremities and/or back. The patient should be reassured and told to treat it symptomatically with analgesics if warranted, which it seldom is.

Allergic reactions.    Occasionally, a patient will have an allergic reaction to the insulin. These are usually manifest in the typical allergic manifestations of skin wheals and/or dyspnea.   These reactions will respond to intramuscular antihistamines and/or subcutaneous Coramine. Also, the patient should be given another 1000 cc enema for this. In individuals with a strong allergic history, it is prudent to give a prophylactic injection of an antihistamine prior to administering the insulin.

"Poor” reactions, "excessive” reactions.    In the case where the patient has no reaction or very little after two hours, he should be given his medications at that time, orally, then intramuscularly, then intravenously with a small amount of hypertonic glucose. The patient should be advised not to take a lot of sweet things until he feels some symptoms of hypoglycemia like hunger or thirst. Even though the patient has had no hypoglycemia, there will still be some beneficial absorption of the medications. At the next treatment, the patient should be given 5 units more insulin than at this treatment.  

In the case where the patient has an excessive reaction, he should have his hypoglycemic condition halted right away with the intravenous hypertonic glucose. This can be finished off with the injections of his intravenous medications; then the oral and intramuscular medications are given.  At the next treatment, the patient should receive 5 units less insulin.



Hypertension. The usual daily doses of antihypertensive medications are withheld on the day of the treatment.

In mild hypertension, the patient is treated as in the uncomplicated case (with the change in the cathartic as mentioned above).  He receives oral, IM, and IV medications with careful monitoring of the IV hypertonic glucose injection, observing for the symptom of headache.

In moderate hypertension, these are the changes from the standard procedure:

-The intramuscular cathartic is given in lower doses as previously mentioned.

-The insulin dose is not calculated on the basis of body weight. These patients are simply given ten units of crystalline rapid-acting insulin intramuscularly and, at the same time, the rest of the intramuscular medications are given.

-After one hour, the oral and intravenous medications are given. The intravenous medications are given in 50% hypertonic glucose as usual. No extra 50% hypertonic glucose is given.

In severe hypertension, these are the changes from the standard procedure:

-The intramuscular cathartic is omitted.

-Ten units of crystalline rapid-acting insulin is given along with all the other intramuscular medications, as described for moderate hypertension.

-One hour later, the oral medications are given, but no intravenous medications are given at all.

-Any symptoms of hypoglycemia experienced by either a moderate or a severe hypertensive are treated with oral forms of sugar. Anything more than mild symptoms of hypoglycemia is an indication to decrease the insulin to 5 units at the next treatment.

Arteriosclerotic heart disease.   In patients with treatable conditions coexisting with any of angina pectoris, rhythm disturbances, or a previous history of cardiac decompensation, there are the following changes from the standard procedure:

-The patient receives no intramuscular cathartic and only a simple water enema.

-The insulin dose is not calculated on the basis of body weight. These patients are given a ten-unit dose of crystalline rapid-acting insulin intramuscularly and, at the same time, all the rest of the intramuscular injections are given.

-After one hour, the oral and intravenous medications are given. The intravenous medications are given in 50% hypertonic glucose as usual. No extra 50% hypertonic glucose is given.

-In ASHD, one always has it in mind to go very slowly with the treatment. Also, one is very attentive to avoid any overt symptoms of hypoglycemia in these patients. Thus, if the patient, after receiving his insulin, even starts to feel a little anxious or experience some diaphoresis, hypertonic glucose is given right away, intravenously, to arrest this. It is important to keep the patient informed of your intention to go slowly in treating his ailments, and to avoid hypoglycemia.

-In those cases where the patient takes some digitalis preparation, it is administered concurrently with the other medications given one hour after the insulin injection. One third of the usual daily dose of cardiotonic agent is given.

Kidney disease.    Patients with chronic renal disease are treated like patients with severe hypertension. They are given ten units of insulin with their IM medications at the same time, and oral medications one hour later. They receive no intravenous medications. Any symptoms of hypoglycemia call for: a) oral sugar and b) reduction of insulin dosage to 5 units at the next treatment.

Febrile conditions .The existence of a fever does not alter any part of Donatian Therapy. Usually the enema alone will bring the fever down to normal. The most important thing in these cases, as always, is to have the proper diagnosis and then to apply the proper indicated medications.

Endocrine and related conditions. The influence of these conditions on Donatian Therapy is significant. This is primarily the result of Donatian Therapy's use of the elements of several of the systems involved in these endocrine-related conditions in its therapeutic undertaking. Following is a description of the interrelationship between Donatian Therapy and these hormone-related disorders and conditions. The lack of some practical details here is the result of the brevity of my clinical experience with some of these conditions.

Adrenal-Related Disorders.   In hypoadrenalism, the patient receives his usual daily medications. These are given at the "therapeutic moment" along with the other medications. Patients on a daily multiple-dose schedule should continue as normal. There is no clinical experience with Cushing-type diseases or pheochromocytoma. The clinical experience evidences that there is a poorer clinical response with Donation Therapy in patients who have had surgical treatment to remove the adrenal or pituitary glands.

Pancreas-Related Disorders.    Patients with diabetes mellitus receive a combination of crystalline and NPH insulin to prepare them for receiving their medications and to maintain a physiologically normal level of blood glucose during the rest of the day of the treatment.  Details of the criteria used for calculating the dosages of the component types of insulin applied are incomplete because of my limited clinical exposure to these cases. I do understand that the calculations are related to the patient's body weight, his fasting blood-glucose level, and a consideration of his current daily insulin intake. Patients on oral hypoglycemic agents do not receive their usual medications on the day of the treatment. The NPH insulin is applied to compensate for this.

There is no clinical experience with insulinomas or patients diagnosed as having reactive hypoglycemia.

Pregnancy.    Under normal circumstances, Donatian Therapy has no ill effects on a developing fetus at any stage of the pregnancy. In women who have a history of spontaneous abortions, there is a chance that a treatment would precipitate another one. The only change made in the therapy for pregnant women is that the intramuscular cathartic is omitted.

Sex-Hormone Related Disorders.    There is no appreciable amount of clinical experience here, except with the menopausal syndrome. Such patients, if on daily hormone supplements, receive their usual medications at the "therapeutic moment". Patients on daily multiple-dose schedules continue as usual on the day of the therapy.

Thyroid-Related Disorders.    There are no basic changes in the application of Donatian Therapy to patients with hypothyroidism. These patients receive their usual daily medications on the day of the treatment, at the "therapeutic moment".  Patients on daily multiple-dose schedules should proceed as usual.

There is no clinical experience with hyperthyroidism.



Except in the case of a pregnant female with a past history of spontaneous abortion, there are no specific diseases in which Donatian Therapy is contraindicated. There are several extreme conditions of the cardiorespiratory system, cachexia, and ascites, etc., wherein the doctor must weight the benefits of the treatment against the possible risks of applying this dynamic therapy in such cases.



            Donatian Therapy exists as a treatment system which enhances the actions of medications on the human body. It is applicable in a wide variety of clinical situations.

This section is presented here to serve as an example of one doctor's adaptation of the principles of this treatment system to his own practice of medicine.

In the Treatment Plans for Specific Diseases that follow, Dr. Perez's choice of drugs, their dosages, and the rationale are given to illustrate his regard for the physiology and pathophysiology of normal and diseased tissues, and how he applies this therapeutically.   Also in this section are presented some particular aspects of Dr. Perez's own practice, including the diagnostic aid which he developed, the Oncodiagnosticador.

As an example of the practice of Donatian Therapy, this present section is incomplete in a significant regard: there is no documentation of any results of clinical experience. Dr. Perez does indeed have a body of documented evidence in his files relating to his experience. While I did look through these, because of the limitations of time and my priorities, I was unable to compile a satisfactorily organized presentation of this for inclusion here.

The presence or absence of clinical proof relating to the efficacy of this form of treatment does not affect the nature of this presentation; its purpose is to promote interest in investigating Donatian Therapy. The treatment plans given in this section may serve as general guidelines for investigation. (See also Lists of Pharmacological Agents)

There are three points that I must make with respect to the following plans:

i) The medications listed here are those applied for primary and secondary therapy.  For clarity, the medications are annotated with a [1] or a [2] as they relate to primary or secondary therapy respectively. These are then described in their appropriate section of the Lists of Pharmacological Agents.

ii) The lists just mentioned are required to clarify the notation indicating the dosages of medications used.  For example, "Madribon I /3" means one-third of the supplied vial, which is one- third of 5 cc containing 500 mg, so that the actual dose indicated by this is 166 mg. In cases where there are many compounds in a single preparation, this is the only notation practicable and, therefore, the one applied throughout this part of the presentation, unless specifically indicated otherwise.

.iii) .This listing of diseases treated by Dr. Perez is most comprehensive. It is through the dynamic application of basic principles of physiology, endocrinology, and pharmacology that Donatian Therapy permits the doctor to deal with such a wide scope of disease processes.



appendicitis, acute

IV:  Reverin [2] 1/3.   Thioderazine [2] 1/3.   Italcal Vit [2] 1 cc,   MgBr [2] 1 cc.

IM:  Reverin [2] 1/3.   Madribon [2] 1/3.   B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Milpar [2] 1 tsp,   Clorostrep [1] 1,   Anaspas-F [2] 1.

Since this is an acute condition, there is no concern as to whether the patient has been fasting or not.

The patient is given neither an enema nor the intramuscular cathartic injection.

The rest of the schedule of the treatment is unchanged with respect to the dosing of insulin by weight, the time of giving the injections, etc.  After the hypoglycemic state has been abolished, the patient receives 500 cc Ringer's Lactate solution intravenously at 70 drops per minute.

The patient's acute abdominal condition should subside with the treatment. If it does not, then the patient is a candidate for surgery.

It is permissible to have a small residual amount of pain in the RLQ after the therapy. In these conditions, the patient is given daily injections of Reverin 2 cc IM b.i.d., and the treatments are repeated every five days until the patient is symptomless.

In most cases, one treatment is sufficient. For eight days following the treatment, the patient should take Milpar 1 tsp b.i.d. and Clorostrep l b.i.d.



IV:  Thioderazine [2] 1/3,   Alin [2] 1/3,   MgBr [2] 2 cc.

IM:  Baralgina [2] 1/3,   Prodolina [2] 1/3,   Lasix [1]  1/3,   Alin [2] 1/3,   Allercur [1] 1/3, Metischol [1] l/3,   B-complex [1] l/3.

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1,   Clorostrep [1] 1.

For treatment purposes, no distinction is made between the different arthritides, except for gouty arthritis, where Uroclasio, five drops, is added to the oral medications.

It is important to do the Oncodiagnosticador test on these patients. Often, experience has shown that the patients will show no response to therapy; then the "Onco" test will be done and show a positive result. Addition of cyclophosphamide to the therapy will now produce a good clinical response. Related to the above, one should always carefully check the female or male genital organs (uterus or prostate) because experience shows that there is a frequent association between neoplasms of these organs and arthritic conditions.  Even without any clinical or "Onco" evidence of uterine or prostatic disease, it is recommended to add some secondary medications for these: eg., Primostat 1/3, Raveron 1/3, and Formula #2 for males; Azowyntomylon 1, and Formula #1 for females.

Therapy between treatments should emphasize vitamins and nutrition (with prohibition of purified carbohydrates, tea, coffee, and nicotine).

After the patient's symptomatic improvement has been maintained for several weeks, the analgesic medications are removed gradually and one continues simply with the primary treatment.   Cessation of treatments follows the guidelines given for this in the Therapeutic Rationale.



IV:  Alin [2] 1/3,   MgBr [2] 2 cc.

IM:  Allercur [1] 1/3,   Lasix [1] 1/3,   Alin [1] 1/3,   Aminophylline [2] 1/3,   B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid[1] 1,   Triqualin [2] 1,   Lasix [1] 1.

This treatment is straightforward primary treatment with conventional secondary therapy. This combined therapy results in a cure and not just short-term medical management, as when secondary medications are applied in the conventional setting.


bladder, carcinoma of

IV:  Reverin [2] 1/3,   Thioderazine [2] 1/3,   Italcal Vit [2] 2 cc,   MgBr [2] 4 cc.

IM:  Madribon [2] 1/3,   Genoxal [2] 1/3,   Lasix [1] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3,   B-complex [1] 1/3.

Oral: Boldocynara [1] I tsp,   Nicotinic acid [1] 1,   Azowyntomylon [2] 1,   Thiola [2] 1.


Bladder / kidneys, infection of

The therapy is much the same as above except one removes the Genoxal from the IM's, the Thioderazine from the IV's, and the Thiola from the oral medications.


breast, carcinoma of

IV:  Reverin [2] 1/3,   Thioderazine [2] 1/3,   Italcal Vit [2] 2 cc,   MgBr [2] 4 cc.

IM:  Reverin [2] 1/3,   Madribon [2] 1/3,   Genoxal [2] 1/3,   Lasix [1] 1/3,   Bhigatoxil [1] 1/3,   B-complex[1] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1, Pleuropon [1] 1, Azowyntomylon [2] 1, Thiola [2] 1.

Experience shows there is a very high association between tumors of the breasts and tumors of the cervix or corpus uteri. Therefore, in treating breast conditions, it is recommended that one treat the female genital tract as well.   Formula #1 is applied as directed here, both with the treatment and during the week.


breasts, benign tumors/cysts of

The therapy is the same as above, with the omission of the Genoxal. It is very important to do the "Onco" test in these cases because what may clinically appear benign can sometimes be premalignant or frankly malignant and require the Genoxal for adequate treatment.


bronchitis, chronic

IV:  Guayabenzo-C [2] 1/3,   Ripason [2] 1/3,   MgBr [2] 2 cc.

IM:  Gadital Yodico [2] 1/3,   Dicristicina [2] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3,   Lasix [1] 1/3,   B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid[1] 1,   Doryl[1] 1,   Ayermicina [2] 1,   Micoren [2] five drops.


bronchogenic carcinoma

The treatment is the same as above, with the following additions:

IM: Genoxal [2] 1/3,   Imferon [2] 1/3,   Ditrei [2] 1/3.

Oral: Thiola [2] 1.

Ayermicina is the preferred antibiotic (IM) for this condition, if it is available.


cervix, carcinoma of

IV:  Reverin [2] 1/3,   Thioderazine [2] 1/3,   Italcal Vit [2] 2 cc,   MgBr [2] 4 cc.

IM:  Reverin [2] 1/3,   Madribon [2] 1/3,   Genoxal [2] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3,   Lasix [1] 1/3.   Metischol [1] 1/3,    B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp, Nicotinic acid [1] 1, Azowyntomylon [2] 1, Thiola [2] 1.

Formula #1 is applied as directed.  In advanced carcinoma of the cervix it is advisable to use the cold suppository form of Formula #1. This should be continued during the week in the liquid form.


cervicitis / vaginitis, chronic

The therapy is the same as above, with the following changes:

IV:  Omit the Thioderazine.
IM:  Omit the Genoxal.
Oral:  Omit the Thiola.


cholelithiasis, cholecystitis

IV:  Glucuronima [1] 1/3,   Cevalin [1] 1/3,   Reverin [2] 1/3,   MgBr [2] 2 cc.
IM:  Novurit [1] 1/3,   Arlidin [1] 1/3,   Mestinon [2] 1/3,   Rifocyna [2] 1/3, Doryl [2] 1/3,   B-complex [ ]1/3.
Oral:  Anaspas-F [2] 1,   
Pleuropon [1] 1,   Lasix [1] 1,   Nicotinic acid [1] 1.

The Doryl is the most important medication here as it is specifically applied for dissolving  the gallbladder calculi.

This medication should be continued in oral form between treatments along with other  indicated interim therapy.


colitis, ulcerative / mucus / mild chronic

IV:  Reverin [2] 1/3,   Ripason [1] 1/3,   Italcal Vit [2] 4 cc,   MgBr [2] 2 cc.  
IM:  Robuden [2] 1/3,   Gefarnil [2] 1/3,   Lasix [1] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3, Metischol 1/3, B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp, Nicotinic acid [1] 1, Carbon [2] 1, Anaspas-F [2] 1, Colymicin [2] 1, (Clorostrep [2] 1).

The carbon tablets are indicated only if the patient has flatulence.

The Anaspas-F is indicated only if the patient has pain of GI spasm.

For "mild chronic colitis," the Robuden and Gefarnil are unnecessary, and Clorostrep is the antibiotic of choice. This condition is a frequent one in many patients, being the accompaniment  of chronic constipation.

A simple water enema, without the IM cathartic, should be used for the first few treatments until the acute local symptoms have subsided. This also applies to cases of carcinoma of the colon and diverticulitis. For simple "mild chronic colitis," proceed as normal.


colon, carcinoma of

The therapy is as for the colitis with the following additions:
IV: Thioderazine [2] 1/3.
IM: Genoxal [2] 1/3.
Oral: Thiola [2] 1.



Much the same pharmacological approach as the above (for colitis) is indicated for this condition. If there is a large inflammatory mass, Thioderazine should be added to the IV medications.



IV:  Reverin [2] 1/3,   MgBr [2] 2 cc.

IM:  Lasix [1] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3,   Madribon [2] 1/3,   Bhigatoxil [1] 1/3,   B-complex [1] 1/3.
Oral:  Boldocynara [1] 1 tsp,   
Nicotinic acid [1] 1,   Cholipin [1] 1,   Azowyntomylon [2] 1.

The therapy is basically primary treatment plus treatment for the patient as if she had an infection.

Formula #1 is also applied as directed.



IV:  Cevalin [1] 1/3,   Italcal Vit [2] 2 cc,   MgBr [2] 2 cc.

IM:   Bhigatoxil [1] 1/3,   Lasix [1] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3,   B-complex [1] 1/3,   Manganol [2] 1/3.
Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1,   Doryl [1] 1.

This therapy is primarily detoxification treatment.

Large doses of vitamin A are given in interim therapy.

Tertiary treatment is very important here, especially as regards the proper physiological functioning of the colon.


epileptic conditions

For treatment purposes, no distinction is made between the different types of epilepsy.

IV:  Novocaina [2] 1/3,   Italcal Vit [2] 2 cc,   MgBr [2] 2 cc.

IM:   Bromars [2] 1/3,   Novocaina [2] 1/3,   Largactil [2] 1/3,   Metischol [1] 1/3,   B-complex1 [1]l 1/3.
Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1,   Doryl [1] 1,   Antisacer [2] 1, Diamox [2] 1,   Glutaphos [2] 1.


hiatus hernia

IV:  Guayabenzo-C [2] 1/3,    Italcal Vit [2] 4 cc.
 Mestinon [2] 1/3,    Prostigmine [2] 1/3,    Lasix [1] 1/3,    Allercur [l] 1/3,    Metischol [1] 1/3,    B-complex [1] 1/3.
Oral:  Boldocynara [1] 1 tsp,    Mucaine [2] 1 tbsp.

The patient receives a plain water enema without IM cathartic.  


hyperactive children

IV:  Novocaina [2] 1/4,   MgBr [2]  2 cc.

IM:  Bromars [2] 1/4,   Manganol [2] 1/4,   Gamibetal [2] 1/4,   B-complex [1] 1/4.
Oral: Boldocynara [1] 1 tsp,   Doryl [1] 1, Pleuropon [1] 1.

Especially important here in tertiary treatment is the complete avoidance of chemical  food additives, particularly artificial flavoring and coloring.



Therapy is simply primary (detoxification) treatment with the addition of the following  secondary therapy:

IM:  Lasix [2] 1/3.

Oral:  Lasix [2] 1,   Hygroton-Reserpina [2] 1.

The Hygroton-Reserpina is administered only in cases of moderate or severe hypertension.


infections, acute, bacterial/viral

For this wide variety of conditions, the following general approach is taken:

The patient is given primary treatment medications for detoxification.

For secondary treatment, various combinations of antibiotic and antiinfective agents are  employed. (Reverin, Madribon, Dicristicina, Ayermicina, Azowyntomylon, etc,.) Dr. Perez routinely includes Reverin and Madribon in these combinations. Choices of other agents are made from consideration of the presenting clinical situation.

For viral infections, it is considered that primary treatment is the most significant factor in the therapeutic endeavor. The antibiotic-antiinfective combinations are also routinely applied to deal with elements of secondary infection in these cases.


poliomyelitis, acute

IV:  D.P.G. [2] 1 cc,   Cevalin [1] 1/4,    Italcal Vit [2] 1 cc,   MgBr [2] 1 cc.  
IM:  Bhigatoxil [1] 1/4,    Arlidin [1] 1/4,    B-complex [1] 1/4,   Reverin [2] 1/4,   Madribon [2] 1/4.

Oral:  Boldocynara [1] 1 tsp,    Nicotinic acid [1] 1/2,   Clorostrep [2] I. `

In these cases, small-volume water enemas are given along with an intramuscular cathartic  consisting of:   Doryl 1/5,    Arlidin 1/4,    Prostigmine 1/5.


poliomyelitis, chronic

Treatment here is rehabilitative. Some very good results have been obtained with these cases. The prognosis varies directly with the degree of the functional disability.

IV:  Dinistenile* [2] 1/4,   Italcal Vit [2] 1 cc,   MgBr [2] 1 cc.

IM:  Neuvi-5 [2] 1/3,   Viryovit [2] 1/3,   B-complex [2] 1/3,   Triduralta [2] 1/3, Arlidin [1] 1/3,   B-complex [1] 1/3.
Oral:  Boldocynara [l] 1 tsp,   
Nicotinic acid [1] 1,    Pengol [2] 1 tsp,    Nucleo CMP [2] 1,    Glutaphos [2] 1.

The male sex hormones, necessary for their protein anabolic effect here, will cause some side effects of virilization.  For female patients, one gives very low doses of these medications ( 1/5 instead of 1/3) and some progesterone along with the treatment. When symptoms of virilization start to show, the Dinistenile* and Viryovit are withdrawn. They may be reintroduced later, depending on the clinical result, the prognosis, and the aims of therapy.

Treatment is continued until there is no more functional amelioration after three successive treatments.

[*Appears as "Dienestile" in the original paper.  We assume it it is Dinistenile.  --IPTQ eds.]


prostate, cancer of

IV:  Reverin [2] 1/3,   Thioderazine [2] 1/3,   Italcal Vit [2] 4 cc,   MgBr [2] 2 cc.

IM:  Reverin [2] 1/3,   Raveron [2] 1/3,   Lasix [1] 1/3,   Alin [1] 1/3,   Allercur [1] 1/3,   Genoxal [2] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1,   Pleuropon [1] 1,   Azowyntomylon [2]  1,   D.E.S. [Diethylstilbesterol] [2] 1,   Thiola [2] 1.

The patient is also advised to apply Formula #2 as directed.


prostatic hypertrophy, benign

The treatment is much the same as the above, except the Genoxal is omitted.



For treatment purposes, no distinction is made between the various types of schizophrenia.

IV:   Novocaina [2] 1/3,   Alin [1] 1/3,   Italcal Vit [2] 2 cc,   MgBr [2] 4 cc.

IM:  Novocaina [2] 1/3,   Bromars [2] 1/3,   Manganol [2] 1/3,   Largactil [2] 1/3,   Lasix [1] 1/3,   Bhigatoxil [1] 1/3,   B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1,   Doryl [1] 1,   Lasix [1] 1.

Detoxification is of the utmost importance in this condition. The patient's gastrointestinal and hepatobiliary systems must be kept functioning adequately if the treatment is to have any success.

In female patients with this condition, the functioning of the pelvic organs is also very important. Therefore, the use of Formula #1 is recommended both during the treatments and during the week.


trauma to spinal cord with paralysis

This type of therapy is rehabilitative. The situation generally is similar to that of chronic polio.

IV:  Dinistenile* [2] 1/3,   MgBr [2] 2 cc.

IM:  Ditrei [2] 1/3,   Imferon [2] 1/3,   Nucleo CMP [2] 1/3,   Arlidin [1] 1/3,   Alin [1] 1/3,   B-complex [1] 1/3.  

Oral:  Boldocynara [1] 1 tsp,   Nicotinic acid [1] 1,   Glutaphos [2] 1/3,   Neurovi-F [2] 1.

[*Appears as "Dienestile" in the original paper.  We assume it it is Dinistenile.  --IPTQ eds.]


ulcers, peptic, gastric or duodenal

IV:  Glucuronima [1] 1/3,   Guayabenzo-C [2] 1/3,   Italcal Vit [2] 4cc,   MgBr [2] 2 cc.

IM:  Gefarnil [2] 1/3,   Robuden [2] 1/3,   Lasix [1] 1/3,   B-complex [1] 1/3.

Oral:  Boldocynara [1] 1 tsp,   Mucaine [2] 1 tbsp,   Gliptide [2] 1,   Doryl [1] 1,   Quimar Oral [2] 1.


ulcers, gastric, malignant

Treatment is much the same as the above, with the addition of the following:  

IV:  Reverin [2] 1/3, Thioderazine [2] 1/3.

IM:  Genoxal [2] 1/3.

Oral:  Thiola [2] 1.  



1. The basic secondary therapy for most malignant neoplastic disease employed by Dr. Perez is:

IV:  Reverin [2] 1/3,   Thioderazine [2] 1/3,   Italcal Vit [1] 4 cc,   MgBr [2] 4 cc.

IM:  Reverin [2] 1/3,   Madribon [2] 1/3,   Genoxal [2] 1/3.

Oral:  Thiola [2] 1.

Additional secondary therapy is applied according to the indications for the particular tissue involved.  Primary Therapy is also applied in all cases.

2. The patients should continue to take Genoxal 50 mg P.O. daily during the therapy, along with any other indicated interim therapy.  Patients who become nauseated on this regimen should discontinue the oral Genoxal.  At the next treatment, the IM Genoxal is withheld also and the doctor concentrates on primary therapy.  Later, both these dosage forms of Genoxal can be re-included, according to the clinical situation.  

3.  For tertiary therapy, patients should be strongly advised to avoid known and suspected carcinogens in their diet and lifestyle such as:
-- the smoke of cigars, cigarettes, and pipes (the patient should know that this means not smoking himself, and staying out of enclosed places where other people are smoking);
-- high cholesterol intake;
-- high animal protein intake;
-- cyclamates, and chemical food additives generally.

4.  Patients who have had previous surgical or extensive radiation therapy should be advised that their treatment will be palliative, and not curative. In Dr. Perez's experience, only one  or two percent of such cases are ever cured of their disease with Donatian Therapy.  This is especially so of cases where there has been surgical removal of the adrenal or pituitary glands.  



Dr. Perez finds it is often useful to give additional intravenous fluids in certain circumstances. The indications and suggested therapy are as follows:

-- Patients whose condition is generally lethargic (before or after therapy), who give a history of chronic anorexia, or who are found to have ketone bodies on urinalysis, should have their treatment followed by an intravenous infusion of 5% dextrose in water with added B-complex vitamins. The amount given is 500 cc, at 70- 80 drops per minute.

-- For those patients who suffer from gastric distention but who still require a source of sugar, 500 cc of 10% dextrose in water is used. This is also run at 70- 80 drops per minute.

-- Experience has also shown that patients who are nauseated after the treatment are benefited by an intravenous infusion of Ringer's Lactate solution (70- 80 drops per minute).



[ Note: The method described below was used in the past, and may be revived in the future.  But  it is still experimental, and we do not know of any doctor or lab using it today.  A small preliminary study  by SGA MD, at McGill University in 1975, found no predictive value.  But the method has not, to my knowledge, been tested in any other laboratory. -- IPTQ.com]

Every patient who undergoes Donatian Therapy in Dr. Perez's clinic has his blood tested by the "Oncodiagnosticador".

Method.  Three cc of serum from a ten cc centrifuged sample of the patient's venous blood is put into a sack formed out of a 4" by 4" sheet of semi-permeable (Pergamine) membrane paper. This is then placed in a 100 cc beaker containing 40 cc of distilled water. It is placed in such a way that the level of the serum in the sack is below that of the water in the beaker. Two thin (I/16th inch) copper wire electrodes are placed in the water on either side of the Pergamine paper sack. The electrodes are connected to the "Oncodiagnosticador" and it is adjusted to create a potential of 32 volts between these electrodes. The power is switched on and the sample is left for two hours; periodic readings of temperature and milliamperage generated in the aqueous reaction medium are taken (every 15 minutes).   After two hours, the power is switched off, a reading of the final pH of the reaction medium is taken, and then the fluid in the sack is transferred to a clear glass test tube in order that its color can be observed against a background of daylight. The apparatus used here, the "Oncodiagnosticador ," is a simple electrical tool consisting of a voltmeter and a milliammeter.

Interpretation.   According to Dr. Perez's experience, this simple and inexpensive test supplies the very valuable information as to whether the patient has some malignant neoplastic process in his body, be it overt, occult, or just a predisposition to the condition.

In a negative test, the serum will retain its characteristic straw-yellow color in most cases.  In a positive test, the serum will have a definite purple-violet color ranging from a deep, almost black shade to a faint violet. The quality of the violet coloration is the important factor, and its degree is important as it relates to the degree of the neoplastic process.

In some sera, negative for cancer according to the above criteria, the color will be gray or brown or even other colors. The brown color indicates extreme toxicity in the individual.  When this color coexists with the violet color (as seen by letting the sample stand overnight so that the brown color layers out in the bottom portion of the test tube), it indicates a poor prognosis for this individual.  The significance of some of the other colors observed in these tests has not yet been ascertained.

[The parameters of temperature, milliamperage, and pH are used by Dr. Perez to help eliminate false positive results and as an aid in the differentiation of borderline positive or negative results obtained in the color reaction. Unfortunately, because of my brief exposure to this procedure and its concepts, I am not able to adequately describe the details concerning the possibilities for differentiation afforded by these other parameters. I can say that in the great majority of test results, the color reaction itself is conclusive, and thus these other parameters are not  of great significance.]

 In the cases where the patient is clinically identifiable as having some malignant neoplastic disease, the "Onco" is useful for determining its degree and the prognosis.  In cases where there has been no previous tissue destruction by surgery or radiation, and there is thus a chance for a cure, the test can indicate when the cure has been obtained, since it then goes negative.

In those cases where the patient does not have any clinically apparent malignant neoplastic disease, and where the "Onco" is positive, the clinical experience has shown repeatedly that no improvement in the patient's condition will occur without specific anticancer therapy (i.e., cyclophosphamide).

Patients who have been cured after Donatian Therapy for a malignant neoplastic process are advised to return to the clinic for follow-up "Onco" tests at quarterly intervals. As with conventional oncology, this follow-up is necessary and the "Onco" makes this a quick and easy procedure.

-Dr. Perez's hypothesis is that the color reaction in this test is caused by some sort of protein moiety. All of his conclusions about this test are drawn from empirically observed correlation. If this procedure is to be regarded seriously, one field of investigation should be an attempt to discover the exact nature of this color reaction and its possible implications for clearer diagnosis and avenues of specific therapy.



The Mexican pharmacological tradition is more consistent with European than North American practice.  For this reason, several of the preparations listed here are unavailable in Canada or the United States.  In a few cases, this is of some significance. Overall, however, I feel that there is sufficient information in these lists, along with Dr. Perez's treatment plans, to give the reader an appreciation of the opportunities for treating diseases medically, using Donatian Therapy.

The preparations described in these Lists of Pharmacological Agents are presented in the following format:

Brand Name, and manufacturer,

-- Generic name and preparation of the product supplied. (Some of these are in Spanish because I was not able to translate the terms with complete accuracy.)

-- Route of administration and usual dosage.

-- Comments on pharmacology. These describe Dr. Perez's rationale for applying the drug preparations.


[I must make two observations that relate to the clarity, or lack of it, in these comments. First, it is Dr. Perez's experience that several drugs have wider ranges of action than current pharmacological wisdom recognizes. This is particularly so for some of the drugs applied in secondary therapy. I have made efforts here to relate Dr. Perez' s own comments without bias. Second, our primary means of communication was the spoken word and this too contributed to some lack of clarity in technical description on account of a language barrier.]


,  Productos Farmaceuticos S.A.

-Dexamethasone sodium phosphate 4 mg, Phenol 5 mg, vehicle 1 cc.

-IV or IM, 1/3 cc.

-This medication, an analog of the steroid hormones, is used for its property of aiding in the process of detoxification via its action in altering the basic metabolic processes of the cells of the body.


Allercur, Schering.

-"Clorhidrato de 1-p-clorbencil-2-pirrolidil-metil bencimidazol"  10 mg, distilled water 1 cc.

-IM, 1/3 cc.

-This medication, an antihistamine, is used primarily in malignant neoplastic disease for its property of aiding in the process of detoxification. No specific mechanism is given.


Arlidin, U.S.V. Pharmaceutical Corp.

-Nylidrin hydrochloride 5 mg, distilled water 1 cc.

-IM, 1/3 cc.

-This medication is used in the intramuscular cathartic and many other primary treatment schedules. It acts as a vasodilator, enhancing transport of metabolic wastes for elimination.


Bhigatoxil, Waltz y Abbat S.A.

-Liver extract (= 5 mcg vitamin B12) 0.33 cc, antitoxic factor of liver 200 mg, vitamin B1 10 mg, vitamin B2 4 mg, vitamin B3 70 mg, vitamin B6 5 mg, vehicle qs 1 cc.

-IM, 1/3 cc.

-Because of its action in stimulating liver function, this preparation is applied frequently in combination with other medications as primary therapy.


Boldocynara, Sandoz de Mexico.

-Dry extract of artichoke 2 gm, dry extract of "boldo" 2 gm, peptones 5 gm, magnesium sulfate 19 gm, filler qs 100 gm.

-Oral, 1 tsp in water.

-This preparation is used in primary therapy because its components act to normalize the digestive function of the gastrointestinal tract.


Cevalin, Lilly.

-Sodium ascorbate l gm, monothioglycerol 0.05 gm, water qs 10 cc.

-IV, 1 /3 vial.

-This medication is used for detoxification in conditions of gallbladder and liver dysfunction.    Dr. Perez says he does not use this preparation in any cases of malignant neoplastic disease because  of its action in increasing the production of lactic acid.


Clorostrep, Parke-Davis.  

-"d (1) trep-p-nitrofenil-2-dicloro-acetamido 1,3-propanodiol" 125 mg, dihydrostreptomycin sulfate 125 mg, in capsule form.

 -Oral, 1 capsule.

-This preparation, a combination of chloramphenicol and streptomycin, is used to combat mild inflammatory conditions in the gastrointestinal tract. To the degree that this aids in normal  function of the GIT, this preparation is useful in detoxification. It is also used as secondary therapy in the treatment of "mild chronic colitis."  

Cholipin, Boeringer Ingelheim.

-" 1,fenil-1-hidroxi-n-pentane" 0.1 gm, "bromuro de dimetil-n-octil-(ester etilico del acid beta-bencilico) amonio" 0.01 gm, in tablet form.

-Oral, 1 tablet.

-This preparation acts as a cholagogue and choleretic and is used in detoxification of the liver.


Doryl, Merck.

-Carbamoylcholinchlorid (Ger.) 2 mg, in tablet form; 0.25 mg/cc, 1 cc vials.  

-Oral, 1 tablet; IM, 1/3 vial.

-This medication is used for its property of aiding in the detoxification process. No specific mechanism is given. Dr. Perez also uses this compound as secondary therapy in certain cases.  (see below.)


Glucuronima, Industria Medical Americana.

-Sodium glucuronide 1 gm, (vial #1), diluent of hydrochloric acid with sodium citrate 190 mg in 5 cc. (vial #2).

-IV, 1/3 prepared vial.

-This medication is specifically indicated for primary therapy where there is dysfunction of the gallbladder.


Lasix, Hoechst.

-Furosemide 40 mg tablets, or 10 mg per cc vials, 2 cc per vial.

-Oral, 1 tablet; IM, 1/3 vial.

–Orally, this medication is applied as secondary therapy for hypertensive conditions. Intramuscularly, its action is more rapid, making it useful for detoxification as it promotes excretion by the kidneys. Dr. Perez says that it also has a direct detoxifying effect on the liver when used by the  intramuscular route.


Mestinon, Roche.

-"Bromure del ester dimetil carbamico del 1-metil-3-hidroxi-piridinio" 1 mg, vehicle 1 cc.

-IM, 1/3 cc.

-This medication is used in the intramuscular cathartic mixture and aids in detoxification by establishing normal peristalsis in the gastrointestinal tract. It is also used as secondary therapy for hiatus hernia (see below).


Metischol, U.S.V. Pharmaceutical Corp.

-Choline chloride 0.2 gm, d-methionine 0.05 gm, inositol 0.1 gm, vitamin BI2 6 mcg, vitamin E 0.03 gm, vehicle 2 cc.

-IM, 1/3 vial.

-This medication contains lipotropic factors, and its application helps in the detoxification of the liver.


Nicotinic acid.

-Nicotinic acid powder 100 mg per capsule.

-Oral I capsule.

-This medication produces generalized vasodilation and aids in the detoxification process by increasing blood flow through tissues allowing the transport of a greater amount of metabolic waste products.


[ Novurit,     A mercury-based diuretic. ]   - IPTQ


Organoatox, Productos Labrapia de Mexico S.A.

-Vitamin B I 25 mg, vitamin B6 25 mg, acid hydrolysate of liver protein (= amino acids): total nitrogen 1.43 mg, acid hydrolysate of adrenal protein (= amino acids): total nitrogen 1.43 mg, phenol 0.004 cc, distilled water qs 1 cc.

-IM, 1/3 cc.

-This preparation is used in cases of extreme toxicity of the organism (indicated by the brown coloration of the "Oncodiagnosticador" test).


Pitocin, Parke-Davis.

-Extract of posterior lobe of pituitary = 10 iu, vehicle I cc.

-IM, 1/3 cc.

-This is used as part of the intramuscular cathartic mixture. Its action of causing contraction of smooth muscle, as in the biliary tree and the gastrointestinal tract, is applied to advantage in the detoxification process.


Pluropon, Boeringer Ingelheim.

-"Silimarina" (Polyhydroxyflavanol) 70 mg, in tablet form.

 -Oral, I tablet.

-This medication is indicated for hepatic insufficiency, acute or chronic hepatitis, amebic hepatic abscesses, fatty degeneration of the liver, passive venous congestion of the liver, and alcoholic cirrhosis. To the degree that it affects hepatic function, it is useful in the process of detoxification.


Ripason, Farmaceuticos Suizos S.A. (Robapharm Suisse.)

-"Extracto total desalbuminado de hidago (liver)" 0.6 gm, metacresol 0.003 gm, vehicle 1 cc.

-IV, 1/3 cc.

-This preparation is used in primary therapy because of its action to stimulate the function of the hepatic cells.


Vitamin B-complex, Merck.

-Vitamin B1 50 mg, vitamin B2 1 mg, vitamin B3 50 mg, vitamin B6 5 mg, alcohol 15 mg,. distilled water 1 cc.

-IM, 1/3 cc.

-To the degree that the B-complex vitamins stimulate liver function, this preparation is used for detoxification. It is also Dr. Perez's experience that its combination with the insulin injection decreases the incidence of allergic reactions to the insulin.




Acidozima, Industria Medical Americana. .

-Cocarboxyllase 50 mg, distilled water 3 cc. (vial # 1 ) Sodium acetate 0.05 gm, distilled water 2 cc. (vial #2) I

-IM, 1/3 combined vials.

-This medication is indicated for diabetic neuropathy.


Alin, Productos Pharmaceuticos S-A.

-Dexamethasone sodium phosphate 4 mg, phenol 5 mg, vehicle 1 cc.

-IV or IM, 1/3 cc.

-In secondary therapy, this medication is used for its antiinflammatory action in the inflammatory arthritides.  It is also used to assist in detoxification in primary therapy.


Aminofilin, Laboratorios Cor., S.A. de C.V.  

-Aminophylline 250 mg, distilled water 10 cc.

-IM, 1/3 vial.

-This medication is indicated in bronchial asthma.


Anaspas-F, Rudefsa.

-"Bromuro de prifinio" 15 mg, in tablet form.

-Oral, 1 tablet.

-This medication is applied for its antispasmodic action in the relief of the pain of gastrointestinal spasm.


Antisacer, Wander.  

-Sodium diphenylhydantoin 0.1 gm, in tablet form.

-Oral, 1 tablet.

-This medication is indicated in the treatment of epileptic disorders.


A.S. Cor, Laboratarios Cor., S.A. de C.V.  

-"Clorhidrato de di-m-oxifenil-1-etanol-1-amino-2 (Novadral)" 0.01 gm, vehicle 2 cc.

-IM, 1/3 vial.

-This medication is used to increase the blood pressure in hypotensive conditions.


Atromid-S, Ayerst.

-Clofibrate, in tablet form.

-Oral, 1 tablet.

-This medication is indicated in the treatment of hypercholesterolemia.


Ayermicina, Ayerst.

-"Leucomicina" (chloramphenicol) 250 mg, in capsule form.

-Oral, 1 capsule.

-This medication is used to combat the infectious component of malignant neoplastic conditions of the bronchi.  


Azowyntomylon, The Sydney Ross Co., S.A.

-Nalidixic acid 500 mg, "clorhidrato de fenazopiridina" 50 mg, filler 775 mg, in tablet form.

-Oral, I tablet.

-This medication is used for its antiinfective and antiinflammatory properties in conditions (including cancer) of the male and female genitourinary systems.


Baralgina, Hoechst de Mexico.

-"Phenyl-dimetil-pirazilon-metilamino-metano-sulfonato-de sodio" 2.5 gm, "clorhidrato de p' piperidino-etoxi-o-carbometoxi-benzofenona " 0.0 I gm, "bromometilado de difenil-piperidino-etil- acetamida" 0.0001 gm, vehicle 5 cc.

-IM, 1/3 vial.

-This medication is an analgesic. It is indicated for the management of the pain of arthritis.


Bromars, Productos Terapeuticos Mexicanos S.A. ,

-" Arrhenal (metil-arseniato de sodio)" 0.035 gm, sodium bromide 0.075 gm, sodium glycerophosphate 0.05 gm, "citrato de hierro amoniacal verde" 0.05 gm, "extracto de valeriana" 0.5 gm, distilIed water 5 cc.

-IM, 1/3 vial.

-This preparation is used in the treatment of schizophrenia and epileptic conditions.



-Charcoal tablets.

-Oral, 1 tablet.

-This is indicated to reduce flatulence in the lower intestinal tract in cases of colitis.


Clorostrep, Parke Davis.

-"d (1) Trep-P-nitrofenil-2-dicloro-acetamido 1, 3 -propanodiol" 125 mg, dihydrostreptomycin sulfate 125 mg, in capsule form.

-Oral, I capsule.

-This preparation is applied in the treatment of "mild chronic colitis", a condition frequently resulting from long standing chronic constipation. This preparation is also used as primary therapy.


[ Colymicin,    an antibiotic. ] - IPTQ


Coramina, Ciba.

-"Dietilamida del acido-piridin-bencarboxilIico" (nikethamide) 0.375 gm, distilIed water 1.5 cc.

-IM, 1/3 vial.

-This medication is applied in the treatment of allergic reactions with a respiratory component. It is also used prophylactically as a cardiac stimulant in patients with arteriosclerotic heart disease.



-This preparation is a mixture of two solutions:

Solution one is "clorhidrato de acriflavina" 1 gm, methylene blue 0.1 gm, "resorcina" 0.05 gm,  distilled water qs 100 cc.

Solution two is hexamethylenotetra-amine of urotropine 25 gm, distilled water qs 100 cc.

-IV, 1 - 4 cc of a 50/50 mixture of solutions # 1 and #2.

-This preparation is no longer available to Dr. Perez but it is included here because of its great usefulness. It is indicated in gynecological infections or neoplastic conditions. Dr. Perez also states that his preparation was very useful for its observed action of decreasing tumor size when applied  along with cyclophosphamide and primary treatment in a wide variety of tumorous conditions. It  is also very valuable for detoxification. No specific mechanisms are given here.

Diamox, Lederle.  

-Acetazolamide 250 mg, in tablet form.

-Oral, 1 tablet.

-This medication is used in epileptic conditions.


Dicristicina S-400, Squibb.  

-Procaine penicillin G 300,000 iu, crystalline potassium penicillin G 100,000 iu, streptomycin sulfate 500 mg, in powder form. (vial # 1 ). Sterile diluent 2 cc. (vial #2).

-IM, 1/3 of the prepared vials.

-This medication is used for the infectious component of bronchogenic carcinoma. It is also indicated for control of other infections in the body caused by susceptible organisms.  


Diethylstilbesterol, Serral.

-Diethylstilbesterol 1 mg, in tablet form.  

-Oral, 1 tablet.

-This medication is indicated in the treatment of prostatic carcinoma. DES, as is commonly recognized, also increases blood flow to the uterine endometrium. It is Dr. Perez's experience that  this compound increases mucosal blood flow in other tissues as well, and thus he uses it to aid in the healing of ulceration of the gastrointestinal mucosa.


Dilar, Syntex.

 -"Paramethasona Syntex" ("21 acetato de 6 alpha-fluoro-16 alpha-metil-meta-cortandrolone") 2 mg, in tablet form.

-Oral, 1 tablet.

-This medication is used for its antiinflammatory action in the inflammation of arthritis.


Dinistenile, Recordati de Mexico S.A.

-Dehydroisoandrosterone sodium sulfate 10 mg, "dinitrillio succinico" 150 mg, distilled water 2 cc.

-IM, 1/3 vial.

-This medication, an anabolic steroid, stimulates regeneration of muscle, skeletal, and nerve tissue. It is indicated in the rehabilitative treatment of the paralysis due to polio and traumatic injuries of the spinal cord.


Ditrei, Italmex S.A.  

-"Dicloroetanato de di-isopropyl amonio" 1 00 mg, chlorbutanol 2 mg, distilled water 2 cc.

-IM, 1/3 vial.

-This medication is used in some cases of malignant neoplastic diseases and dysfunctional conditions  of the CNS. It increases the utilization of available oxygen through a direct vasodilator action and by stimulation of mitochondrial oxido-reductase enzyme systems.


Doryl, Merck.

-"Carbamylcholinchlorid" (Ger.) 2 mg, in tablet form; 0.25 mg/cc, 1 cc vials.

-Oral, 1 tablet; IM, 1/3 vial

-Pharmacologically, this medication is a choline ester with strong nicotinic effects. In Dr. Perez's experience, this drug has a specific action to dissolve gallbladder and renal calculi. He states that the parenteral (IM) form, which is no longer available to him in Mexico, is more efficacious than the oral form. No specific mechanism is given here.


Dropilac, Lepetit.

-"Complejo atomizado de leche y silicato de sodio y aluminio en pulvo" I .4 gm, glycine 0.333 gm, filler 2.7 gm, in tablet form.

-Oral, I tablet.

-This preparation is indicated to counteract the hyperacidity accompanying ulcerative conditions of the stomach and duodenum.


Effortil, Boeringer Ingelheim.

-1 -(3-oxyphenyl) 1-oxy-2-ethyl-aminoethane hydrochloride 7.5 mg, distilled water 1 cc.

-Oral, five drops.

-This preparation is used as a CNS stimulant and is indicated in senility as well as in the management of hypotensive conditions.


Fedal Piperin, Hobson.

-Piperazine adipate 300 mg, in tablet form.

-Oral, 1 tablet.

-This medication is indicated in parasitic infestations of the intestinal tract.


Formula #1.

-This is a combination developed by Dr. Perez, of several preparations. It is composed of:

1) Genoxal 100 mg, dry powder;

2) Crystalline insulin 40 units/cc, 5cc. (The Genoxal is dissolved in this.)

3) Madribon 500 mg per 5 cc vial, 2 vials.

4) Synalar with Neosporin ointment (0.01% fluocinolone acetonide, 0.35% neomycin sulfate), one 30 gm tube.

5) Quimar Unguento (tryspin-chymotrypsin: total activity 1,000,000 units, neomycin sulfate 350 mg, hydrocortisone acetate 250 mg), one 15 gm tube.

All of these preparations are mixed together and refrigerated in a darkened glass container. A cold suppository form can be made with two cc. of this formulation, hardened in an aluminum foil mould immersed in crushed dry ice.

-Vaginally, 1 cc with 1 cc of air squirted from a 5 cc syringe (without the needle). This is given at the time of the actual treatment in the clinic and, as well, the patient is instructed to administer the 1 cc amount, twice per day at home, between successive treatments. The patient should be advised to remain supine for one half-hour after each application.

In cases of advanced carcinoma of the cervix, with a clearly identifiable ulcerated lesion, the cold suppository form of the formula is used at the time of the treatment. This is introduced through a speculum using a surgical clamp, the idea being to actually deposit the suppository within the ulcerated lesion. Here too, the patient is instructed to use the liquid form at home, twice per day, between treatments.

-Formula #1 is indicated in all gynecological conditions of the vagina, cervix, and corpus uteri, whether these be infectious or neoplastic processes. The various components of this formulation act to reduce inflammation and infection, liquefy necrotic debris, and directly attack cancerous cells.


Formula #2.  

-This is a combination developed by Dr. Perez, of several preparations. It is composed of:

1) Diprasone (betamethasone dipropionate 0.05%), one 15 gm tube.

2) Quadriderm (tolnaftate lO gm %, iodochlorhydroxyquin 1 gm %, 17-betamethasone valerate 61 mg %, gentamycin sulfate = 100 mg % gentamycin base), one 15 mg tube.

3) Lasonil (Heparanoid Bayer 5,000 units, hyaluronidase 15,000 units), one 30 gm tube.

4) Kenacomb (triamcinolone acetonide 1 mg %, neomycin sulfate = 2.5 mg% neomycin base, gramicidin 0.25 mg %, nystatin 100,000 units), one 12 gm tube.

All of these preparations are mixed together and refrigerated in a darkened glass container.

-The patient is instructed to put a finger-tip full of this formulation in and around the urethral meatus twice per day. The patient is advised to empty his bladder before each application.

-Forrnula #2 is indicated in conditions involving the prostate, be they infectious, benign, or malignant. The various components of this formulation act to decrease inflammation and infection in the urethra and the prostate.


Gadital Yodico, Italmex S.A.

 -"Yodo" 0.01 gm, guayacol 0.1 gm, eucalyptol 0.1 gm, menthol 0.05 gm, vitamin A 4,000 iu, vitamin D 1,000 iu, prepared in 5 cc "aceites de hidago de bacalao y sesamo".

-IM, 1/3 vial.

-This preparation is used in infectious conditions of the respiratory tract, especially chronic bronchitis. It is also used, in combination with Dicristicina S-400, for bronchogenic carcinoma.


Gamibetal, Italmex S.A.

-Alpha amino beta-hydroxy butyric acid 0.25 gm, distilled water 2 cc.

-IM, 1/3 vial.

-This medication is applied by Dr. Perez in conditions characterized by functional hyperactivity of the nervous system, such as agitated neuroses and insomnia. This compound is a constituent of the normal reserve of amino acids in the brain, and thus plays a role in regulating the altered physiological processes of the CNS.  


Gefarnil, Recordati de Mexico S.A.

-"Farnesilacetato de geranilo" 50 mg, distilled water 1 cc.  

-IM, 1/3 vial.

-This medication has a specific trophism for the gastrointestinal mucosa and is thus used to aid in the healing of gastric and duodenal ulceration.  


Genoxal, Merck.

-Cyclophosphamide 500 mg, sodium chloride 225 mg, as dry powder, distilled water 10 cc.  

-IM, 1/3 vial.

-This medication is indicated in the treatment of malignant neoplastic diseases.  


Gliptide, Merck.

-This preparation is a semisynthetic polypeptide composed of:   ileu 0.15%, val 0.45%, ala 0.59%, pro 2.7%, ser 0.87%, asp 0.25%, leu 0.49%, hist 0.36%, gly 0.4%, glut A 0.75%, threo 2.78%, tyro tr, lys 0.23%, arg 0.24%, fucose 3.3%, galactose 9.7%, glucosamine 12%, galactosamine 7.8%, sialic acid 2.3%, "az sulfonico" 14%, "grupos acetico" 4.8%, in tablet form.

-Oral, 1 tablet.

-This medication is indicated for the treatment of gastric and duodenal ulcers because of its mucoprotector, antipeptic, and antichlorhydric activities.


Glutaphos, Laboratorios Carnot.

-Glutamic acid 0.4 gm, "inositohexafosfato de calcio y magnesio" 0.075 gm, vitamin B12 15 mcg, vitamin D 700 iu, vitamin A 5,000 iu, in tablet form.

-Oral, 1 tablet.

-This medication stimulates functional regeneration of nervous tissue and is indicated in multiple sclerosis, mental retardation, polio, and traumatic injury to the CNS.


Guayabenzo-C, Laboratorios Leuttier S.A.

-Crystallized guayacol 0.1 gm, sodium benzoate 1.0 gm, distilled water qs lO cc. (vial #1).  Vitamin C 500 mg, distilled water 1.5 cc (vial #2).

-IV, 1/3 of vial #1, or 1/3 of the combination of vials #1 and #2.

-This preparation is used for infections of the respiratory tract, (both vials # 1 and #2). Dr. Perez also uses the vial # 1 alone to treat gastritis and gastric ulcers because the sodium benzoate component helps reduce acid conditions of the gastric mucosa and thus helps to reduce inflammation.


Hygroton Reserpina, Geigy.

-Hygroton 50 mg, reserpine 0.25 mg, in tablet form.

-Oral, 1 tablet.

-This medication is indicated in moderate to severe hypertensive conditions.


Imferon, Farmaceuticos Lakeside S.A.

-Complex of iron dextran equivalent to 0.05 gm elemental iron, phenol (preservative) 0.005 gm, distilled water 1 cc.

-IM, 1/3 vial.

-This medication is used to stimulate hematopoiesis in anemic conditions.


Insulin, Lilly.

-Crystalline insulin (porcine) 40 units per cc.

-IM, dosage depends on body weight or other mitigating clinical circumstances. (See earlier section on “The use of insulin in Donatian Therapy”.)

-Dr. Perez uses insulin according to the principles of Donatian Therapy in order to effect changes in the therapeutic terrain within the organism to the end of: i) aiding in the process of cellular detoxification by producing a favorable synergy with other medications used in primary therapy; and ii) potentiating the actions of medications applied as secondary therapy during that phase of the induced hypoglycemia called the "therapeutic moment."  Insulin effects these changes physiologically, through a combination of its action on cell-membrane permeability and extensive alterations in the physico-chemical constituents of the body-fluid compartments (see earlier section on Donatian Therapy: Theory).


Italcalcio Vitaminico, Italmex S.A.

-Calcium gluconate 0.5 gm, "zimolactato de calcio" 0.35 gm, "cansulfonato de calcio" 0.1 gm, "formiato de calcio" 0.05 gm, soluble vitamin D 500 iu, distilled water qs 10 cc.

-IV, 1 - 4 cc.

-This preparation is used as a calcium supplement in a wide variety of conditions. It helps in the antitoxic function of the gastrointestinal tract by regulating humoral conditions required for normal peristalsis. Calcium administration is also important in the treatment of malignant neoplastic conditions, especially carcinoma of the prostate.


Largactil, Rhodia mex.

-Chlorpromazine 25 mg, distilled water 5 cc.  

-IM, 1/3 vial.

-This medication is indicated in the treatment of schizophrenia and epileptic conditions.


Lasix, Hoechst.  

-Furosemide, 40 mg per tablet.

-Oral, 1 tablet.

-Here, this medication is used in the treatment of mild hypertensive conditions.


Madribon, Roche.  

-Sodium 2,4-dimethoxy-6-sulfanilamide I, 3-diazine 530 mg, (= 500 mg medication), distilled water 5 cc.

-IM, 1/3 vial.

-Dr. Perez applies this preparation in synergy with antibiotic medications as an antiseptic factor in malignant neoplastic diseases.  


Magnesium Bromide.

-Magnesium bromide, chemically pure, 25 gm, dissolved in 100 cc distilled water.  -IV, 1 -4 cc.

-Dr. Perez uses this magnesium solution in practically all the treatments he applies. This mineral is required for normal functioning of the CNS and many enzyme systems. In Dr. Perez's experience,  there is usually a deficit of this in malignant neoplastic disease.


Manganol, Laboratoratorios Farbar.  

-" Abietato de manganesio" 0.01 gm, sesame oil 2 cc.

-IM, 1/3 vial.  

-Dr. Perez uses this as a specific antitoxic medication in allergic conditions of the respiratory and gastrointestinal systems and in the atopic dermatoses. This mineral preparation is also used in schizophrenia and epileptic conditions.


Mestinon, Roche.

-"Bromuro del ester dimetil carbamico del 1-metil-3-hidroxi-piridinio" 1 mg, vehicle 1 cc.  

-IM, 1/3 vial.

-As secondary therapy, this medication is used in the treatment of hiatus hernia because of its action in causing contraction of smooth muscle. It is applied in the intramuscular cathartic (primary  therapy) because of its action on intestinal smooth muscle to establish normal peristalsis.


Micoren, Geigy.

-"Dimetilamida del acido-n-crotoniI-alpha etilamino butirico" 112.5 mg, "dietilamida del acido-n-crotonil alpha propilamino butirico" I 12.5 mg, distilled water 1.5 cc.

-Oral, five drops.

-This preparation is a respiratory analeptic and it is used in conditions such as carcinoma of the lung, asthma, and conditions of respiratory acidosis.  



-Magnesium hydroxide 5.76 gm, liquid petrolatum 25 cc, in 100 cc aqueous suspension.

-Oral, I tbsp.

-This medication is used in acute appendicitis to help reduce the inflammation of the mucosa.


Minocin, Lederle.

-Minocin hydrochloride 100 mg, in tablet form.

-Oral, I tablet.

-This antibiotic is used for infections of the respiratory tract due to susceptible organisms.


Mucaine, Wyeth Vales.

-Aluminum hydroxide 81 cc, magnesium hydroxide 1.95 gm, "oxetazaina" 0.2 gm, vehicle qs 100 cc.

-Oral, I tbsp.

-This preparation is used in ulcerative and inflammatory conditions of the gastrointestinal tract.


Neurovi-F, Productos Terapeuticos Mexicanos S.A.

-Calcium and magnesium inositohexaphosphate 0.25 gm, "keto-hidro estrina" 0.0001 gm, brain extract (= 6 mg brain) 0.15 gm, bone marrow extract (= 6 mg) 0.15 gm, vitamin B1 2.0 mg, vitamin B2 1.25 mg, filler 0.75 gm, in tablet form.

-Oral, 1 tablet.

-This medication is indicated in the rehabilitative treatment of polio and traumatic CNS injuries with paralysis.


Nuevi-5, Productos Terapeuticos Mexicanos S.A.

-Vitamin B1 100 mg, vjtamin B12 100 mcg, inositohexaphosphate of sodium and magnesium 100 mg, extract of brain (= 2 mg fresh brain) 1 gm, extract of bone marrow 1 gm, sterile isotonic sodium chloride solution 5 cc.

-IM, 1/3 vial.

-This medication is indicated in the rehabilitative treatment of chronic polio and traumatic CNS injuries with paralysis.


Novocaina, Fabwerke Hoechst.

-Novocaine hydrochloride 2%, distilled water 5 cc.

-IV or IM, 1/3 vial.

-This medication is indicated in schizophrenia, epileptic conditions, and functional hyperactivity of the CNS (agitated neuroses).


Nucleo CMP, Novag.

-i) Vitamin B12 1 mg, cytidine-5'-monophosphate 2.5 mg, uridine-5'-monophosphate 1.5 mg, in capsule form. ii) Vitamin B12 2 mg, cytidine-5'-monophosphate 5 mg, uridine-5'-triphosphate 3 mg, mannitol 40 mg, (vial # I ). Lidocaine hydrochloride 20 mg, distilled water 2 cc (vial #2).

-Oral, 1 tablet; IM, 1/3 of prepared vials #1 and #2.

-This preparation has an action to stimulate myelinization of the elements of the nervous system.  Dr. Perez uses it in mental retardation, multiple sclerosis, and senile conditions characterized by loss of memory.



-Magnesium hydroxide 5.76 gm, liquid petrolatum 25 cc, in 100 cc aqueous suspension.

-Oral, I tbsp.

-This medication is used in acute appendicitis to help reduce the inflammation of the mucosa.


Minocin, Lederle.

-Minocin hydrochloride 100 mg, in tablet form.

-Oral, I tablet.

-This antibiotic is used for infections of the respiratory tract due to susceptible organisms.


Mucaine, Wyeth Vales.

-Aluminum hydroxide 81 cc, magnesium hydroxide 1.95 gm, "oxetazaina" 0.2 gm, vehicle qs 100 cc.

 -Oral, I tbsp.

-This preparation is used in ulcerative and inflammatory conditions of the gastrointestinal tract.


Neurovi-F, Productos Terapeuticos Mexicanos S.A.

-Calcium and magnesium inositohexaphosphate 0.25 gm, "keto-hidro estrina" 0.0001 gm, brain extract (= 6 mg brain) 0.15 gm, bone marrow extract (= 6 mg) 0.15 gm, vitamin B1 2.0 mg, vitamin B2 1.25 mg, filler 0.75 gm, in tablet form.

-Oral, 1 tablet.

-This medication is indicated in the rehabilitative treatment of polio and traumatic CNS injuries with paralysis.


Nuevi-5, Productos Terapeuticos Mexicanos S.A.

-Vitamin B1 100 mg, vitamin B12 100 mcg, inositohexaphosphate of sodium and magnesium 100 mg, extract of brain (= 2 mg fresh brain) 1 gm, extract of bone marrow 1 gm, sterile isotonic sodium chloride solution 5 cc.

-IM, 1/3 vial.

-This medication is indicated in the rehabilitative treatment of chronic polio and traumatic CNS injuries with paralysis.


Novocaina, Fabwerke Hoechst.

-Novocaine hydrochloride 2%, distilled water 5 cc.

-IV or IM, 1/3 vial.

-This medication is indicated in schizophrenia, epileptic conditions and functional hyperactivity of the CNS (agitated neuroses).


Nucleo CMP, Novag.

-i) Vitamin B12 1 mg, cytidine-5'-monophosphate 2.5 mg, uridine-5'-monophosphate 1.5 mg, in capsule form. ii) Vitamin B12 2 mg, cytidine-5'-monophosphate 5 mg, uridine-5'-triphosphate 3 mg, mannitol 40 mg, (vial # I). Lidocaine hydrochloride 20 mg, distilled water 2 cc (vial #2).

-Oral, 1 tablet; IM, 1/3 of prepared vials #1 and #2.

-This preparation has an action to stimulate myelinization of the elements of the nervous system.  Dr. Perez uses it in mental retardation, multiple sclerosis, and senile conditions characterized by loss of memory


Primostat, Schering.  

-"Capronato de gestonorona" 200 mg, distilled water 2 cc.

-IM, 1/3 vial.

-This medication is indicated in benign prostatic hypertrophy, carcinoma of the prostate, and advanced carcinoma of the uterine endometrium.


Prodolina, Promeco.

 -"Dimetil-oxquinazina-metileno-metilamino-sulfonato de magnesio 2.15 gm, distilled water 5 cc. I 1

-IM, 1/3 vial.

-This medication is a non-narcotic analgesic, and it is used in a wide variety of conditions with a component of visceral or somatic pain.  


Prostigmine, Roche.

-"Ester: dimetilcarbamidico del monometilsulfato de trimetil-3-hidroxifenil amonio" 0.5 mg, sodium chlonde 8.35 mg, distilled water qs 1 cc.

-IM, 1/3 vial.

-This medication is used as a smooth muscle stimulant in the treatment of hiatus hernia.


 Quimar Oral, Armour Pharmaceutical Co.

-Concentrated proteolytic enzymes: trypsin and chymotrypsin 50,000 units, in tablet form.  

-Oral, 1 tablet.

-This preparation is used by Dr. Perez in the treatment of carcinoma of the stomach and for ulcerative conditions of the stomach and duodenum. It is used for its direct action on these  lesions when applied by the oral route.


Raveron, Farmaceuticos Suizos S.A. (for Robapharm S.A., Basel, Switzerland).  

-"Extracto desalbuminado hidrosoluble de 0.43 gm de prostata" 0.013 gm, metacresol 0.0003 gm, distilled water 1 cc.

-IM, 1/3 vial.

-This medication is used in the treatment of all prostatic conditions (prostatitis, BPH, carcinoma of the prostate). It acts by influencing the secretive and proliferative activity of the cells of the gland.


Reverin, Hoechst.

-i) "Pirrolidino-metil-tetracilina" 150 mg, xylocaine hydrochloride 40 mg, vehicle 2 cc in vials for  IM administration. ii) "Pirrolidino-metil-tetraciclina" 275 mg, distilled water lO cc in vials for IV administration.

-IM, 1/3 vial; IV, 1/3 vial.

 -Dr. Perez applies these preparations in a wide variety of circumstances to combat the infectious and inflammatory conditions that co-exist with many diseases, including the malignant neoplastic ones.



-Rifamycin 250 mg, vitamin C 25 mg, lidocaine hydrochloride 10 mg, distilled water qs 3 cc.  

-IM, 1/3 vial.

-This medication is indicated in inflammatory or infectious conditions of the gallbladder and biliary system.


Robuden-D, Farmaceuticos Suizos S.A.

-"Extracto hidrosoluble de 0.42 gr de estomaco" 0.3 cc, "extracto hidrosoluble de 0.63 gm de intestino delgado" 0.7 cc. in l cc vials.

-IM, 1/3 vial.

-This medication has a mucoprotective action in the gastrointestinal tract and also decreases the activity of peptic enzymes and regulates GI motility. It is indicated in ulcerative and neoplastic conditions of the gastrointestinal tract.


Thiola, Colliere S.A.

-"Mercaptopropioniglicina " 100 mg, filler 480 mg, in tablet form.

-Oral, l tablet.

-This medication is indicated as specific detoxification therapy in neoplastic diseases. It acts to remove toxic heavy metals from the organism.


Tace, Merrell.

-Chlortriansene 0.012 gm, in capsule form.

 -Oral, I capsule.

-This medication is indicated for conditions involving the prostate, and in the management of the menopausal syndrome.


Tandenom, Coliere S.A.

-"Extracto de corteza Pygeum Africanum" 25 mg, filler 155 mg, in tablet form.

-Oral, 1 tablet.

-This preparation is indicated for infectious, benign, and malignant conditions of the prostate.


Thioderazine B-Midy, Farmaceuticos Suizos S.A.

-"Diamida sulfocarbonica" 0.001 gm, "di-yodo-metilato de dimetildietilendiamina" 0.1 gm, "hexahidrato de piperazina" 0.05 gm, benzoic acid 0.012 gm, chloroethane 0.005 gm, distilled water 5 cc (vial # l ). Thiamine hydrochloride 250 mg, distilled water 2 cc (vial #2).

-IV, 1/3 of the prepared combination of vials # 1 and #2.

-This medication is listed in the Mexican pharmacopeia as being indicated to dissolve tophaceous deposits in gouty arthritis. In Dr. Perez's experience, this preparation is valuable for decreasing the size of tumor masses when applied along with other secondary therapy for malignant neoplastic disease. It is Dr. Perez's opinion that it is the salts of iodine in the preparation that is responsible for this observed effect. No specific mechanism is given.


Triqualin, Farmaceuticos Suizos S.A.

-"Tritoqualina" 75 mg, chlorpheniramine maleate 2 mg, in tablet form.

-Oral, I tablet.

-This preparation is an antihistaminic. It is used in allergic conditions and in bronchial asthma.


Uroclasio, Italmex S.A.

-"Bioxido de silicio al estabo colloidial" 0.25 gm, potassium carbonate 0.025 gm, sodium chloride 0.19 gm, cesium carbonate 0.05 gm, distilled water qs 100 cc.

-Oral, five drops.

-This preparation is used to decrease the uric acid concentration in cases of gouty arthritis.


Viryovit, Productos Terapeuticos Mexicanos.

-Testosterone propionate 0.025 gm, vitamin E 0.05 gm, vitamin A 0.02 gm, "yodo organico en solucion oleosa" 0.04 gm, sesame oil 2 cc.

-IM, 1/3 vial.

-This preparation is used in the rehabilitative treatment of chronic polio and traumatic CNS injury because of its protein anabolic effect.


Yodobetin, Laboratorios Funck.

-"Yodohidrato de betaino" 100 mg, vitamin B1 0.5 mg, vitamin B2 1 mg, vitamin B3 10 mg, vitamin B6 0.1 mg, calcium pantothenate 0.5 mg, protein hydrolysate of casein and yeast containing amino acids, in tablet form.

-Oral, 1 tablet.

-This preparation is used, along with other secondary therapy, for malignant neoplastic disease, to decrease tumor size by virtue of its content of iodine salts. No specific mechanism for this is given.




In between successive applications of Donatian Therapy, Dr. Perez continues to treat his patients with medications and advice about lifestyle. This interim therapy follows the division into primary, secondary, and tertiary levels, as described above.

For primary therapy, the patients are usually given some vitamin B complex preparations with liver extract, and a cathartic (magnesium salts). These are given by the oral route, daily. In cases where the patient has a proper physiologically functioning colon, the daily cathartic preparation is unnecessary.

Secondary therapy differs little from conventional pharmacotherapy for diseases, following established indications. The commonest medications that Dr. Perez prescribes here are analgesic, antibiotic, antiinflammatory, and antineoplastic agents. He docs not use narcotic preparations, nor any of the common sedative or hypnotic preparations. The experience here indicates that because of the beneficial effects of the therapy itself, these types of medications are unnecessary.

The aim of the counseling concerning lifestyle, or tertiary therapy, is to encourage  the patient to effect changes here to the end of being able to function in continued good health, after cessation of the treatments, without requiring any further prescription medications.



The scientific endeavor of modern medicine has left no stone unturned in its search to elucidate the basic pathophysiological processes that afflict the human body. Through my medical education and training and subsequent practice of medicine as a general practitioner, I have had the opportunity to learn and work within this most advanced and technologically sophisticated system of medical therapy.

In this presentation I have attempted to communicate, in full, my experience with  and understanding of a dynamic new approach to medical therapy. I have done this at such length because I have learned something new from the concepts and principles that embody Donatian Therapy.

I have learned to consider the physiology of the human body as if it were a tool that could be intelligently applied to therapeutic advantage in dealing with the pathophysiology of disease.

Applying physiology according to the practice of Donatian Therapy, it seems that the result is to potentiate and enhance the actions of many commonly used allopathic medicines. As a corollary of this, an improved therapeutic response may be obtained using just these medicines in this way.  


This level: Up ] Syphilis 1938 ] EstenosisPilóricas ] Pyloric Stenosis ] [ Donatian Therapy 1976 ] Uruguay 2003 ] 

Site index: Home ] Choosing IPT ] Find a Doctor ] IPT Training ] . ] About IPT ] Cancer ] Other Diseases ] Doctors Listing ] First Doctors ] Patient Stories ] Patients Home ] Articles & pubs ] Books ] Action ! ] . ] News ] Search ] Site Index ] . ] About Us ] Links ] Tell A Friend ]

Tell a friend about IPTQ.com
Entire IPTQ website Copyright © 1999-2002 by Chris Duffield, Ph.D.  All rights reserved.
IPTQ, IPTQ.org, IPTQ.com, IPTQ.net, The second discovery of insulin, and IPTQ lifering and lifeboat logos are trademarks. 
Please read the IPTQ.com disclaimer.   
This page was last updated on  March 19, 2008.
Website technical corrections and suggestions -- email to IPTQ Webhost.
Please also visit GetIPT.com
website visitors since August 2002
Click on box for detailed statistics)

Chris Duffield, webhost